<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Nat Commun</journal-id>
      <journal-id journal-id-type="iso-abbrev">Nat Commun</journal-id>
      <journal-title-group>
        <journal-title>Nature Communications</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2041-1723</issn>
      <publisher>
        <publisher-name>Nature Publishing Group UK</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">32001716</article-id>
      <article-id pub-id-type="pmc">6992768</article-id>
      <article-id pub-id-type="publisher-id">14360</article-id>
      <article-id pub-id-type="doi">10.1038/s41467-020-14360-7</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Loss-of-function mutations in <italic>UDP-Glucose 6-Dehydrogenase</italic> cause recessive developmental epileptic encephalopathy</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" equal-contrib="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9773-2667</contrib-id>
          <name>
            <surname>Hengel</surname>
            <given-names>Holger</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Bosso-Lef&#xE8;vre</surname>
            <given-names>C&#xE9;lia</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Grady</surname>
            <given-names>George</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Szenker-Ravi</surname>
            <given-names>Emmanuelle</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Li</surname>
            <given-names>Hankun</given-names>
          </name>
          <xref ref-type="aff" rid="Aff6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pierce</surname>
            <given-names>Sarah</given-names>
          </name>
          <xref ref-type="aff" rid="Aff7">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0419-8547</contrib-id>
          <name>
            <surname>Lebigot</surname>
            <given-names>&#xC9;lise</given-names>
          </name>
          <xref ref-type="aff" rid="Aff8">8</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tan</surname>
            <given-names>Thong-Teck</given-names>
          </name>
          <xref ref-type="aff" rid="Aff9">9</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Eio</surname>
            <given-names>Michelle Y.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff9">9</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Narayanan</surname>
            <given-names>Gunaseelan</given-names>
          </name>
          <xref ref-type="aff" rid="Aff9">9</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Utami</surname>
            <given-names>Kagistia Hana</given-names>
          </name>
          <xref ref-type="aff" rid="Aff10">10</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yau</surname>
            <given-names>Monica</given-names>
          </name>
          <xref ref-type="aff" rid="Aff11">11</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Handal</surname>
            <given-names>Nader</given-names>
          </name>
          <xref ref-type="aff" rid="Aff12">12</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Deigendesch</surname>
            <given-names>Werner</given-names>
          </name>
          <xref ref-type="aff" rid="Aff12">12</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Keimer</surname>
            <given-names>Reinhard</given-names>
          </name>
          <xref ref-type="aff" rid="Aff13">13</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Marzouqa</surname>
            <given-names>Hiyam M.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff12">12</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gunay-Aygun</surname>
            <given-names>Meral</given-names>
          </name>
          <xref ref-type="aff" rid="Aff14">14</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Muriello</surname>
            <given-names>Michael J.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff14">14</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Verhelst</surname>
            <given-names>Helene</given-names>
          </name>
          <xref ref-type="aff" rid="Aff15">15</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Weckhuysen</surname>
            <given-names>Sarah</given-names>
          </name>
          <xref ref-type="aff" rid="Aff16">16</xref>
          <xref ref-type="aff" rid="Aff17">17</xref>
          <xref ref-type="aff" rid="Aff18">18</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mahida</surname>
            <given-names>Sonal</given-names>
          </name>
          <xref ref-type="aff" rid="Aff19">19</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Naidu</surname>
            <given-names>Sakkubai</given-names>
          </name>
          <xref ref-type="aff" rid="Aff19">19</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Thomas</surname>
            <given-names>Terrence G.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff20">20</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lim</surname>
            <given-names>Jiin Ying</given-names>
          </name>
          <xref ref-type="aff" rid="Aff21">21</xref>
          <xref ref-type="aff" rid="Aff22">22</xref>
          <xref ref-type="aff" rid="Aff23">23</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tan</surname>
            <given-names>Ee Shien</given-names>
          </name>
          <xref ref-type="aff" rid="Aff21">21</xref>
          <xref ref-type="aff" rid="Aff22">22</xref>
          <xref ref-type="aff" rid="Aff23">23</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Haye</surname>
            <given-names>Damien</given-names>
          </name>
          <xref ref-type="aff" rid="Aff24">24</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Willemsen</surname>
            <given-names>Mich&#xE8;l A. A. P.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff25">25</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7146-617X</contrib-id>
          <name>
            <surname>Oegema</surname>
            <given-names>Renske</given-names>
          </name>
          <xref ref-type="aff" rid="Aff26">26</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mitchell</surname>
            <given-names>Wendy G.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff27">27</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1985-3671</contrib-id>
          <name>
            <surname>Pierson</surname>
            <given-names>Tyler Mark</given-names>
          </name>
          <xref ref-type="aff" rid="Aff28">28</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5448-1204</contrib-id>
          <name>
            <surname>Andrews</surname>
            <given-names>Marisa V.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff29">29</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Willing</surname>
            <given-names>Marcia C.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff29">29</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rodan</surname>
            <given-names>Lance H.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff30">30</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1231-1562</contrib-id>
          <name>
            <surname>Barakat</surname>
            <given-names>Tahsin Stefan</given-names>
          </name>
          <xref ref-type="aff" rid="Aff31">31</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>van Slegtenhorst</surname>
            <given-names>Marjon</given-names>
          </name>
          <xref ref-type="aff" rid="Aff31">31</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gavrilova</surname>
            <given-names>Ralitza H.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff32">32</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Martinelli</surname>
            <given-names>Diego</given-names>
          </name>
          <xref ref-type="aff" rid="Aff33">33</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3060-422X</contrib-id>
          <name>
            <surname>Gilboa</surname>
            <given-names>Tal</given-names>
          </name>
          <xref ref-type="aff" rid="Aff34">34</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tamim</surname>
            <given-names>Abdullah M.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff35">35</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hashem</surname>
            <given-names>Mais O.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff36">36</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>AlSayed</surname>
            <given-names>Moeenaldeen D.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff37">37</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Abdulrahim</surname>
            <given-names>Maha M.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff37">37</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Al-Owain</surname>
            <given-names>Mohammed</given-names>
          </name>
          <xref ref-type="aff" rid="Aff37">37</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Awaji</surname>
            <given-names>Ali</given-names>
          </name>
          <xref ref-type="aff" rid="Aff38">38</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mahmoud</surname>
            <given-names>Adel A. H.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff39">39</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Faqeih</surname>
            <given-names>Eissa A.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff40">40</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Asmari</surname>
            <given-names>Ali Al</given-names>
          </name>
          <xref ref-type="aff" rid="Aff40">40</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Algain</surname>
            <given-names>Sulwan M.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff41">41</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jad</surname>
            <given-names>Lamyaa A.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff39">39</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Aldhalaan</surname>
            <given-names>Hesham M.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff42">42</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8486-0558</contrib-id>
          <name>
            <surname>Helbig</surname>
            <given-names>Ingo</given-names>
          </name>
          <xref ref-type="aff" rid="Aff43">43</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Koolen</surname>
            <given-names>David A.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff44">44</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Riess</surname>
            <given-names>Angelika</given-names>
          </name>
          <xref ref-type="aff" rid="Aff45">45</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kraegeloh-Mann</surname>
            <given-names>Ingeborg</given-names>
          </name>
          <xref ref-type="aff" rid="Aff46">46</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bauer</surname>
            <given-names>Peter</given-names>
          </name>
          <xref ref-type="aff" rid="Aff45">45</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3897-1238</contrib-id>
          <name>
            <surname>Gulsuner</surname>
            <given-names>Suleyman</given-names>
          </name>
          <xref ref-type="aff" rid="Aff7">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Stamberger</surname>
            <given-names>Hannah</given-names>
          </name>
          <xref ref-type="aff" rid="Aff16">16</xref>
          <xref ref-type="aff" rid="Aff17">17</xref>
          <xref ref-type="aff" rid="Aff18">18</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ng</surname>
            <given-names>Alvin Yu Jin</given-names>
          </name>
          <xref ref-type="aff" rid="Aff47">47</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tang</surname>
            <given-names>Sha</given-names>
          </name>
          <xref ref-type="aff" rid="Aff48">48</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tohari</surname>
            <given-names>Sumanty</given-names>
          </name>
          <xref ref-type="aff" rid="Aff47">47</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Keren</surname>
            <given-names>Boris</given-names>
          </name>
          <xref ref-type="aff" rid="Aff49">49</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7222-9985</contrib-id>
          <name>
            <surname>Schultz-Rogers</surname>
            <given-names>Laura E.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff32">32</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Klee</surname>
            <given-names>Eric W.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff32">32</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7307-388X</contrib-id>
          <name>
            <surname>Barresi</surname>
            <given-names>Sabina</given-names>
          </name>
          <xref ref-type="aff" rid="Aff33">33</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tartaglia</surname>
            <given-names>Marco</given-names>
          </name>
          <xref ref-type="aff" rid="Aff33">33</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mor-Shaked</surname>
            <given-names>Hagar</given-names>
          </name>
          <xref ref-type="aff" rid="Aff50">50</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Maddirevula</surname>
            <given-names>Sateesh</given-names>
          </name>
          <xref ref-type="aff" rid="Aff36">36</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Begtrup</surname>
            <given-names>Amber</given-names>
          </name>
          <xref ref-type="aff" rid="Aff51">51</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Telegrafi</surname>
            <given-names>Aida</given-names>
          </name>
          <xref ref-type="aff" rid="Aff51">51</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pfundt</surname>
            <given-names>Rolph</given-names>
          </name>
          <xref ref-type="aff" rid="Aff44">44</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sch&#xFC;le</surname>
            <given-names>Rebecca</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ciruna</surname>
            <given-names>Brian</given-names>
          </name>
          <xref ref-type="aff" rid="Aff11">11</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bonnard</surname>
            <given-names>Carine</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pouladi</surname>
            <given-names>Mahmoud A.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff10">10</xref>
          <xref ref-type="aff" rid="Aff52">52</xref>
          <xref ref-type="aff" rid="Aff53">53</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Stewart</surname>
            <given-names>James C.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff47">47</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Claridge-Chang</surname>
            <given-names>Adam</given-names>
          </name>
          <xref ref-type="aff" rid="Aff47">47</xref>
          <xref ref-type="aff" rid="Aff54">54</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lefeber</surname>
            <given-names>Dirk J.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff55">55</xref>
          <xref ref-type="aff" rid="Aff56">56</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4158-341X</contrib-id>
          <name>
            <surname>Alkuraya</surname>
            <given-names>Fowzan S.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff36">36</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4591-5274</contrib-id>
          <name>
            <surname>Mathuru</surname>
            <given-names>Ajay S.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff6">6</xref>
          <xref ref-type="aff" rid="Aff47">47</xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3620-0277</contrib-id>
          <name>
            <surname>Venkatesh</surname>
            <given-names>Byrappa</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
          <xref ref-type="aff" rid="Aff47">47</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Barycki</surname>
            <given-names>Joseph J.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Simpson</surname>
            <given-names>Melanie A.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jamuar</surname>
            <given-names>Saumya S.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff21">21</xref>
          <xref ref-type="aff" rid="Aff22">22</xref>
          <xref ref-type="aff" rid="Aff23">23</xref>
          <xref ref-type="aff" rid="Aff57">57</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Sch&#xF6;ls</surname>
            <given-names>Ludger</given-names>
          </name>
          <address>
            <email>ludger.schoels@uni-tuebingen.de</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4070-7997</contrib-id>
          <name>
            <surname>Reversade</surname>
            <given-names>Bruno</given-names>
          </name>
          <address>
            <email>bruno@reversade.com</email>
          </address>
          <xref ref-type="aff" rid="Aff3">3</xref>
          <xref ref-type="aff" rid="Aff4">4</xref>
          <xref ref-type="aff" rid="Aff47">47</xref>
          <xref ref-type="aff" rid="Aff58">58</xref>
          <xref ref-type="aff" rid="Aff59">59</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2190 1447</institution-id><institution-id institution-id-type="GRID">grid.10392.39</institution-id><institution>Department of Neurology and Hertie-Institute for Clinical Brain Research, </institution><institution>University of T&#xFC;bingen, </institution></institution-wrap>T&#xFC;bingen, Germany </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0438 0426</institution-id><institution-id institution-id-type="GRID">grid.424247.3</institution-id><institution>German Center of Neurodegenerative Diseases (DZNE), </institution></institution-wrap>T&#xFC;bingen, Germany </aff>
        <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0367 4692</institution-id><institution-id institution-id-type="GRID">grid.414735.0</institution-id><institution>Institute of Medical Biology, A*STAR, Biopolis, </institution></institution-wrap>Singapore, 138648 Singapore </aff>
        <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2180 6431</institution-id><institution-id institution-id-type="GRID">grid.4280.e</institution-id><institution>National University of Singapore, Department of Paediatrics, </institution><institution>Yong Loo Lin School of Medicine, Biopolis, </institution></institution-wrap>Singapore, Singapore </aff>
        <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2173 6074</institution-id><institution-id institution-id-type="GRID">grid.40803.3f</institution-id><institution>Department of Molecular and Structural Biochemistry North Carolina State University, </institution></institution-wrap>Raleigh, NC 27607 USA </aff>
        <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 4651 0380</institution-id><institution-id institution-id-type="GRID">grid.463064.3</institution-id><institution>Yale-NUS College, 12 College Avenue West, Biopolis, </institution></institution-wrap>Singapore, Singapore </aff>
        <aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000000122986657</institution-id><institution-id institution-id-type="GRID">grid.34477.33</institution-id><institution>Division of Medical Genetics, Department of Medicine, </institution><institution>University of Washington, </institution></institution-wrap>Seattle, WA USA </aff>
        <aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2181 7253</institution-id><institution-id institution-id-type="GRID">grid.413784.d</institution-id><institution>Service De Biochimie, </institution><institution>Hopital Bic&#xEA;tre, Assistance publique-H&#xF4;pitaux de Paris, 78 avenue du general leclerc, </institution></institution-wrap>Le Kremlin Bic&#xEA;tre, France </aff>
        <aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0637 0221</institution-id><institution-id institution-id-type="GRID">grid.185448.4</institution-id><institution>Institute of Medical Biology, </institution><institution>Singapore Stem Cell Bank, A&#x2217;STAR, Biopolis, </institution></institution-wrap>Singapore, 138648 Singapore </aff>
        <aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0637 0221</institution-id><institution-id institution-id-type="GRID">grid.185448.4</institution-id><institution>Translational Laboratory in Genetic Medicine, Agency for Science, </institution><institution>Technology, and Research, Singapore (A*STAR), 8A Biomedical Grove, Immunos, Level 5, </institution></institution-wrap>Singapore, 138648 Singapore </aff>
        <aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2157 2938</institution-id><institution-id institution-id-type="GRID">grid.17063.33</institution-id><institution>Program in Developmental &amp; Stem Cell Biology, The Hospital for Sick Children, Department of Molecular Genetics, </institution><institution>The University of Toronto, </institution></institution-wrap>Toronto, ON Canada </aff>
        <aff id="Aff12"><label>12</label>Caritas Baby Hospital Bethlehem, Bethlehem, State of Palestine </aff>
        <aff id="Aff13"><label>13</label>Ped Neurology, Staufer Hospital, Wetzgauer Stra&#xDF;e 85, Schw&#xE4;bisch-Gm&#xFC;nd, Germany </aff>
        <aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2171 9311</institution-id><institution-id institution-id-type="GRID">grid.21107.35</institution-id><institution>McKusick-Nathans Institute of Genetic Medicine, </institution><institution>Johns Hopkins University School of Medicine, </institution></institution-wrap>Baltimore, MD 21205 USA </aff>
        <aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0626 3303</institution-id><institution-id institution-id-type="GRID">grid.410566.0</institution-id><institution>Department of Paediatric Neurology, </institution><institution>Ghent University Hospital, </institution></institution-wrap>Ghent, Belgium </aff>
        <aff id="Aff16"><label>16</label><institution-wrap><institution-id institution-id-type="ISNI">0000000104788040</institution-id><institution-id institution-id-type="GRID">grid.11486.3a</institution-id><institution>Center for Molecular Neurology, VIB, </institution></institution-wrap>Antwerp, Belgium </aff>
        <aff id="Aff17"><label>17</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0790 3681</institution-id><institution-id institution-id-type="GRID">grid.5284.b</institution-id><institution>Laboratory of Neurogenetics, Institute Born-Bunge, </institution><institution>University of Antwerp, </institution></institution-wrap>Antwerp, Belgium </aff>
        <aff id="Aff18"><label>18</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0626 3418</institution-id><institution-id institution-id-type="GRID">grid.411414.5</institution-id><institution>Department of Neurology, </institution><institution>University Hospital Antwerp, </institution></institution-wrap>Antwerp, Belgium </aff>
        <aff id="Aff19"><label>19</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0427 667X</institution-id><institution-id institution-id-type="GRID">grid.240023.7</institution-id><institution>Division of Neurology and Neurogenetics, </institution><institution>Kennedy Krieger Institute, </institution></institution-wrap>Baltimore, MD USA </aff>
        <aff id="Aff20"><label>20</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 8958 3388</institution-id><institution-id institution-id-type="GRID">grid.414963.d</institution-id><institution>Neurology Service, Department of Paediatrics, </institution><institution>KK Women&#x2019;s and Children&#x2019;s Hospital, </institution></institution-wrap>Singapore, Singapore </aff>
        <aff id="Aff21"><label>21</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 8958 3388</institution-id><institution-id institution-id-type="GRID">grid.414963.d</institution-id><institution>Genetics Service, Department of Paediatrics, </institution><institution>KK Women&#x2019;s and Children&#x2019;s Hospital, </institution></institution-wrap>Singapore, Singapore </aff>
        <aff id="Aff22"><label>22</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0385 0924</institution-id><institution-id institution-id-type="GRID">grid.428397.3</institution-id><institution>Paediatric Academic Clinical Programme, </institution><institution>Duke-NUS Medical School, </institution></institution-wrap>Singapore, Singapore </aff>
        <aff id="Aff23"><label>23</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2180 6431</institution-id><institution-id institution-id-type="GRID">grid.4280.e</institution-id><institution>SingHealth Duke-NUS Genomic Medicine Centre, </institution></institution-wrap>Singapore, Singapore </aff>
        <aff id="Aff24"><label>24</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2322 4179</institution-id><institution-id institution-id-type="GRID">grid.410528.a</institution-id><institution>Service de G&#xE9;n&#xE9;tique M&#xE9;dicale, </institution><institution>CHU De Nice H&#xF4;pital de l&#x2019;Archet 2, 151 route Saint Antoine de la Ginesti&#xE8;re, CS 23079 062002, </institution></institution-wrap>Nice, Cedex 3 France </aff>
        <aff id="Aff25"><label>25</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0444 9382</institution-id><institution-id institution-id-type="GRID">grid.10417.33</institution-id><institution>Department of Pediatric Neurology, </institution><institution>Radboud University Medical Center, </institution></institution-wrap>Nijmegen, The Netherlands </aff>
        <aff id="Aff26"><label>26</label><institution-wrap><institution-id institution-id-type="ISNI">0000000090126352</institution-id><institution-id institution-id-type="GRID">grid.7692.a</institution-id><institution>Department of Genetics, </institution><institution>University Medical Center Utrecht, </institution></institution-wrap>Utrecht, The Netherlands </aff>
        <aff id="Aff27"><label>27</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2156 6853</institution-id><institution-id institution-id-type="GRID">grid.42505.36</institution-id><institution>Neurology Division, Childrens Hospital Los Angeles &amp; Department of Neurology, </institution><institution>Keck School of Medicine of University of Southern California, </institution></institution-wrap>Los Angeles, CA 90033 USA </aff>
        <aff id="Aff28"><label>28</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2152 9905</institution-id><institution-id institution-id-type="GRID">grid.50956.3f</institution-id><institution>Department of Pediatrics, Department of Neurology, &amp; the Board of Governors Regenerative Medicine Institute, </institution><institution>Cedars-Sinai Medical Center, </institution></institution-wrap>Los Angeles, CA USA </aff>
        <aff id="Aff29"><label>29</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2355 7002</institution-id><institution-id institution-id-type="GRID">grid.4367.6</institution-id><institution>Division of Genetics and Genomic Medicine, Department of Pediatrics, </institution><institution>Washington University School of Medicine, </institution></institution-wrap>St. Louis, MO USA </aff>
        <aff id="Aff30"><label>30</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0378 8438</institution-id><institution-id institution-id-type="GRID">grid.2515.3</institution-id><institution>Division of Genetics and Genomics and Department of Neurology, </institution><institution>Boston Children&#x2019;s Hospital, </institution></institution-wrap>Boston, MA USA </aff>
        <aff id="Aff31"><label>31</label><institution-wrap><institution-id institution-id-type="ISNI">000000040459992X</institution-id><institution-id institution-id-type="GRID">grid.5645.2</institution-id><institution>Department of Clinical Genetics, Erasmus MC, </institution><institution>University Medical Center, Wytemaweg 80, </institution></institution-wrap>3015 CN Rotterdam, The Netherlands </aff>
        <aff id="Aff32"><label>32</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0459 167X</institution-id><institution-id institution-id-type="GRID">grid.66875.3a</institution-id><institution>Department of Clinical Genomics, </institution><institution>Mayo Clinic, </institution></institution-wrap>200 First Street SW, Rochester, MN USA </aff>
        <aff id="Aff33"><label>33</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0727 6809</institution-id><institution-id institution-id-type="GRID">grid.414125.7</institution-id><institution>Genetics and Rare Diseases Research Division, </institution><institution>Ospedale Pediatrico Bambino Ges&#xF9;, IRCCS, viale San Paolo 15, </institution></institution-wrap>00146 Rome, Italy </aff>
        <aff id="Aff34"><label>34</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2221 2926</institution-id><institution-id institution-id-type="GRID">grid.17788.31</institution-id><institution>Child Neurology Unit, </institution><institution>Hadassah-Hebrew University Medical Center, </institution></institution-wrap>9112001 Jerusalem, Israel </aff>
        <aff id="Aff35"><label>35</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2191 4301</institution-id><institution-id institution-id-type="GRID">grid.415310.2</institution-id><institution>Pediatric Neurology, </institution><institution>King Faisal Specialist Hospital and Research Center, </institution></institution-wrap>Riyadh, Saudi Arabia </aff>
        <aff id="Aff36"><label>36</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2191 4301</institution-id><institution-id institution-id-type="GRID">grid.415310.2</institution-id><institution>Department of Genetics, </institution><institution>King Faisal Specialist Hospital and Research Center, </institution></institution-wrap>Riyadh, Saudi Arabia </aff>
        <aff id="Aff37"><label>37</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2191 4301</institution-id><institution-id institution-id-type="GRID">grid.415310.2</institution-id><institution>Department of Medical Genetics, </institution><institution>King Faisal Specialist Hospital and Research Center, </institution></institution-wrap>Riyadh, Saudi Arabia </aff>
        <aff id="Aff38"><label>38</label>Department of Pediatrics, King Fahad Central Hospital in Jizan, Abu Arish, Saudi Arabia </aff>
        <aff id="Aff39"><label>39</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0593 1832</institution-id><institution-id institution-id-type="GRID">grid.415277.2</institution-id><institution>Pediatric Neurology Department, National Neuroscience Institute, </institution><institution>King Fahad Medical City, </institution></institution-wrap>Riyadh, Saudi Arabia </aff>
        <aff id="Aff40"><label>40</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0593 1832</institution-id><institution-id institution-id-type="GRID">grid.415277.2</institution-id><institution>Section of Medical Genetics, </institution><institution>Children&#x2019;s Hospital, King Fahad Medical City, </institution></institution-wrap>Riyadh, Saudi Arabia </aff>
        <aff id="Aff41"><label>41</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0593 1832</institution-id><institution-id institution-id-type="GRID">grid.415277.2</institution-id><institution>General Pediatrics and Adolescents, </institution><institution>King Fahad Medical City, </institution></institution-wrap>Riyadh, Saudi Arabia </aff>
        <aff id="Aff42"><label>42</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2191 4301</institution-id><institution-id institution-id-type="GRID">grid.415310.2</institution-id><institution>Neuroscience Department King Faisal Specialist Hospital and Research Center, </institution></institution-wrap>Riyadh, Saudi Arabia </aff>
        <aff id="Aff43"><label>43</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0680 8770</institution-id><institution-id institution-id-type="GRID">grid.239552.a</institution-id><institution>Division of Neurology, </institution><institution>The Children&#x2019;s Hospital of Philadelphia, </institution></institution-wrap>Philadelphia, PA USA </aff>
        <aff id="Aff44"><label>44</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0444 9382</institution-id><institution-id institution-id-type="GRID">grid.10417.33</institution-id><institution>Department of Human Genetics, </institution><institution>Radboud University Medical Center, </institution></institution-wrap>Nijmegen, The Netherlands </aff>
        <aff id="Aff45"><label>45</label>Institute of Medical Genetics and Applied Genomics (T&#xFC;bingen) and Centogene AG (Rostock), Rostock, Germany </aff>
        <aff id="Aff46"><label>46</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2190 1447</institution-id><institution-id institution-id-type="GRID">grid.10392.39</institution-id><institution>Department of Pediatric Neurology, </institution><institution>University of T&#xFC;bingen, </institution></institution-wrap>T&#xFC;bingen, Germany </aff>
        <aff id="Aff47"><label>47</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0637 0221</institution-id><institution-id institution-id-type="GRID">grid.185448.4</institution-id><institution>Institute of Molecular and Cell Biology, </institution><institution>A*STAR, Biopolis, </institution></institution-wrap>Singapore, 138673 Singapore </aff>
        <aff id="Aff48"><label>48</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0455 211X</institution-id><institution-id institution-id-type="GRID">grid.465138.d</institution-id><institution>Division of Clinical Genomics, Ambry Genetics, </institution></institution-wrap>Aliso Viejo, CA USA </aff>
        <aff id="Aff49"><label>49</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2150 9058</institution-id><institution-id institution-id-type="GRID">grid.411439.a</institution-id><institution>APHP, GH Piti&#xE9; Salp&#xEA;tri&#xE8;re, Department of Genetics, Unit of Development Genomics, </institution></institution-wrap>Paris, France </aff>
        <aff id="Aff50"><label>50</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2221 2926</institution-id><institution-id institution-id-type="GRID">grid.17788.31</institution-id><institution>Department of Genetic and Metabolic Diseases, </institution><institution>Hadassah-Hebrew University Medical Center, </institution></institution-wrap>9112001 Jerusalem, Israel </aff>
        <aff id="Aff51"><label>51</label><institution-wrap><institution-id institution-id-type="GRID">grid.428467.b</institution-id><institution>GeneDx, 207 Perry Parkway, </institution></institution-wrap>Gaithersburg, MD 20877 USA </aff>
        <aff id="Aff52"><label>52</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2180 6431</institution-id><institution-id institution-id-type="GRID">grid.4280.e</institution-id><institution>Department of Physiology, </institution><institution>National University of Singapore, </institution></institution-wrap>Singapore, 117597 Singapore </aff>
        <aff id="Aff53"><label>53</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2180 6431</institution-id><institution-id institution-id-type="GRID">grid.4280.e</institution-id><institution>Department of Medicine, </institution><institution>National University of Singapore, </institution></institution-wrap>Singapore, 117597 Singapore </aff>
        <aff id="Aff54"><label>54</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0385 0924</institution-id><institution-id institution-id-type="GRID">grid.428397.3</institution-id><institution>Program in Neuroscience and Behavioral Disorders, </institution><institution>Duke-NUS Medical School, </institution></institution-wrap>Singapore, Singapore </aff>
        <aff id="Aff55"><label>55</label>Department of Neurology, Donders Center for Brain, Cognition, and Behavior, Nijmegen, The Netherlands </aff>
        <aff id="Aff56"><label>56</label>Department of Laboratory Medicine, Translational Metabolic Laboratory, Nijmegen, The Netherlands </aff>
        <aff id="Aff57"><label>57</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2180 6431</institution-id><institution-id institution-id-type="GRID">grid.4280.e</institution-id><institution>SingHealth Duke-NUS Institute of Precision Medicine, </institution></institution-wrap>Singapore, Singapore </aff>
        <aff id="Aff58"><label>58</label><institution-wrap><institution-id institution-id-type="ISNI">0000000106887552</institution-id><institution-id institution-id-type="GRID">grid.15876.3d</institution-id><institution>Medical Genetics Department, </institution><institution>Ko&#xE7; University School of Medicine, </institution></institution-wrap>34010 Istanbul, Turkey </aff>
        <aff id="Aff59"><label>59</label><institution-wrap><institution-id institution-id-type="ISNI">0000000404654431</institution-id><institution-id institution-id-type="GRID">grid.5650.6</institution-id><institution>Reproductive Biology Laboratory, Obstetrics and Gynaecology, </institution><institution>Academic Medical Center (AMC), Meibergdreef 9, </institution></institution-wrap>1105 AZ Amsterdam-Zuidoost, The Netherlands </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>30</day>
        <month>1</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>30</day>
        <month>1</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2020</year>
      </pub-date>
      <volume>11</volume>
      <elocation-id>595</elocation-id>
      <history>
        <date date-type="received">
          <day>20</day>
          <month>9</month>
          <year>2017</year>
        </date>
        <date date-type="accepted">
          <day>19</day>
          <month>12</month>
          <year>2019</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2020</copyright-statement>
        <license license-type="OpenAccess">
          <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article&#x2019;s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x2019;s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p id="Par1">Developmental epileptic encephalopathies are devastating disorders characterized by intractable epileptic seizures and developmental delay. Here, we report an allelic series of germline recessive mutations in <italic>UGDH</italic> in 36 cases from 25 families presenting with epileptic encephalopathy with developmental delay and hypotonia. <italic>UGDH</italic> encodes an oxidoreductase that converts UDP-glucose to UDP-glucuronic acid, a key component of specific proteoglycans and glycolipids. Consistent with being loss-of-function alleles, we show using patients&#x2019; primary fibroblasts and biochemical assays, that these mutations either impair UGDH stability, oligomerization, or enzymatic activity. In vitro, patient-derived cerebral organoids are smaller with a reduced number of proliferating neuronal progenitors while mutant <italic>ugdh</italic> zebrafish do not phenocopy the human disease. Our study defines UGDH as a key player for the production of extracellular matrix components that are essential for human brain development. Based on the incidence of variants observed, <italic>UGDH</italic> mutations are likely to be a frequent cause of recessive epileptic encephalopathy.</p>
      </abstract>
      <abstract id="Abs2" abstract-type="web-summary">
        <p id="Par2">UDP-glucuronic acid is a component of the extracellular matrix. Here, the authors report biallelic variants in the gene encoding UDP-Glucose 6-Dehydrogenase (UGDH) in individuals affected by developmental epileptic encephalopathies that impair UGDH stability, oligomerization, or enzymatic activity in vitro.</p>
      </abstract>
      <kwd-group kwd-group-type="npg-subject">
        <title>Subject terms</title>
        <kwd>Glycobiology</kwd>
        <kwd>Clinical genetics</kwd>
        <kwd>Neuronal development</kwd>
        <kwd>Encephalopathy</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2020</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Introduction</title>
      <p id="Par3">Developmental epileptic encephalopathies are a clinically and genetically heterogeneous group of devastating disorders characterized by severe epileptic seizures that are accompanied by developmental delay or regression<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. In several cases, a genetic etiology has been identified<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. Germline mutations in these genes lead to different pathophysiological defects<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>, including ion channel dysfunction, synaptic impairment, transporter defects and metabolic abnormalities, such as deficiencies in glycosylation pathways<sup><xref ref-type="bibr" rid="CR3">3</xref>&#x2013;<xref ref-type="bibr" rid="CR5">5</xref></sup>. However, the genetic cause of many epileptic encephalopathies remains unknown.</p>
      <p id="Par4">Defects of glycosylation are causing more than 100 rare human genetic disorders, most of these affecting the central and/or peripheral nervous systems. Patients typically show developmental delay or intellectual disability, seizures, neuropathy, and metabolic abnormalities in multiple organ systems<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. Adding the correct sugar chains (glycans) to proteins and lipids significantly impacts their function. <italic>UGDH</italic> (MIM603370) codes for an enzyme that converts UDP-glucose (UDP-Glc) to UDP-glucuronic acid (UDP-GlcA) through the concomitant reduction of NAD<sup>+</sup> into NADH<sup><xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR7">7</xref></sup>. UDP-GlcA is not only needed for detoxification via glucuronidation, but is also an obligate precursor for the synthesis of glycosaminoglycans (GAGs), and therefore an important component of proteoglycans of the extracellular matrix.</p>
      <p id="Par5">In this study, we establish <italic>UGDH</italic> as a gene responsible for autosomal recessive developmental epileptic encephalopathy in humans. We catalog a series of 30 patients from 25 families with biallelic germline <italic>UGDH</italic> variants. Using patients&#x2019; primary fibroblasts and biochemical assays, we demonstrate that these are loss-of-function alleles. While mutant <italic>ugdh</italic> zebrafish did not phenocopy the disease, we bring evidence that patient-derived cerebral organoids, which were smaller due to a reduced number of proliferating neuronal progenitors, can serve as an alternative disease-in-a-dish model for in vitro functional studies.</p>
    </sec>
    <sec id="Sec2" sec-type="results">
      <title>Results</title>
      <sec id="Sec3">
        <title>Biallelic mutations in <italic>UGDH</italic> cause developmental epileptic encephalopathy</title>
        <p id="Par6">To identify the genetic cause of a developmental epileptic encephalopathy in a consanguineous Palestinian family with three affected siblings (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1a</xref>, F1), we performed exome sequencing on two affected siblings. No mutations in genes known to be associated with neurological disorders (either recessive or dominant) were found. As the consanguineous background and the pedigree suggested autosomal recessive inheritance, we focused on homozygous or compound heterozygous variants shared by the affected siblings. A rare homozygous variant c.131C&#x2009;&gt;&#x2009;T in <italic>UDP-Glucose 6-Dehydrogenase</italic> (<italic>UGDH)</italic>, which changes alanine into valine at position 44 of the UGDH protein, was the only segregating candidate variant. The <italic>UGDH</italic> p.A44V missense affects a highly conserved residue (Suppl. Fig.&#xA0;<xref rid="MOESM1" ref-type="media">1b</xref> and phyloP 100-way<sup><xref ref-type="bibr" rid="CR8">8</xref></sup> score 9.43), is extremely rare in public databases (not present in EVS6500<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>, MAF of 0.0017% in ExAC<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>) and is a good candidate according to in silico prediction scores (CADD score<sup><xref ref-type="bibr" rid="CR11">11</xref></sup> of 33) (Suppl. Table&#xA0;<xref rid="MOESM1" ref-type="media">1</xref>). We then (i) screened the GENESIS<sup><xref ref-type="bibr" rid="CR12">12</xref></sup> database for additional patients with recessive <italic>UGDH</italic> variants, (ii) contacted the EuroEPINOMICS RES Consortium, and (iii) searched with the help of GeneMatcher<sup><xref ref-type="bibr" rid="CR13">13</xref></sup> for additional families with germline <italic>UGDH</italic> mutations. We uncovered 27 additional patients from 24 families carrying either compound heterozygous or homozygous <italic>UGDH</italic> variants (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1a</xref> and Suppl. Fig.&#xA0;<xref rid="MOESM1" ref-type="media">1a</xref>). All variants were absent or had an extremely low frequency (&lt;0.01%) in the public databases ExAC/gnomAD<sup><xref ref-type="bibr" rid="CR10">10</xref></sup> and EVS6500 (Suppl. Table&#xA0;<xref rid="MOESM1" ref-type="media">2</xref>). Nineteen of the 20 identified missense variants are in highly conserved residues (Suppl. Fig.&#xA0;<xref rid="MOESM1" ref-type="media">1b</xref> and phyloP 100-way between 3.81 and 9.43). The A44V variant, identified in the Palestinian index family, was also found in two additional families from Puerto Rico (F11) and from Spain (F13) indicative of independent but recurrent mutation in this residue. In ExAC the A44V variant is observed in African (MAF 0.0096%) and European (Non-Finish) populations (MAF 0.0015%), however, it is not present in the Greater Middle East Variome.<fig id="Fig1"><label>Fig. 1</label><caption><title>Clinical and genetic findings in 21 affected individuals diagnosed with Jamuar Syndrome consisting of&#xA0;developmental epileptic encephalopathy.</title><p><bold>a</bold> Pedigrees of 19 families segregating autosomal recessive developmental epileptic encephalopathy. Countries of origin are specified above each pedigree. Filled black symbols, affected individuals. Crossed symbols, deceased individual. Mutations in UGDH protein are presented below pedigrees. Homozygous mutations are presented in bold (<italic>m</italic> in the pedigrees). Compound heterozygous mutations are presented according to the parental origin of the mutation with a maternal origin in the first row (<italic>m1</italic> in the pedigrees), and a paternal, de novo or unknown origin in the second row (<italic>m2</italic> in the pedigrees). Healthy siblings that could be sequenced are heterozygous [F6-II:2 (p.Arg65*), F11-II:2 (p.Ala44Val), and F18-II:3 (p.Arg317Gln)]. <bold>b</bold> Facial photographs of 14 affected individuals with mild craniofacial dysmorphisms, including short and flattened philtrum, protruding earlobes, ptosis blepharophimosis, and epicanthic folds. <bold>c</bold> Spectrum of MRI findings in exemplary patients showing no evidence for maldevelopment but displaying variable abnormalities ranging from abnormal myelination and/or cerebral or cerebellar atrophy, to normal findings. Patient F5-II:2 presented with a normal MRI, including normal myelination at 2 years of age. In contrast, MRI of patient F3-II:1 revealed some myelination of cerebellar peduncles at 5 months (arrow) and no progress of myelination on follow-up at 15 months, indicative of hypomyelination. In addition, repeated MRI revealed enlarged posterior ventricles over time (arrow heads). MRI of patient F6-II:1 at 7 days of age also proved normal, the circle indicates onset of myelination in the Posterior Limb of the Internal Capsule (PLIC) according to age. Patient F7-II:1 showed mild cerebellar atrophy at 4 years of age. Patient F9-II:1 showed slightly delayed myelination on axial T2 and cerebellar atrophy on coronal and sagittal T1 images (stars). Patient F14-II:1 showed a diffuse cerebral atrophy, ventriculomegaly, thin corpus callosum, vermian, and lobar cerebellar atrophy, with normal brainstem, hyperintensity of cerebellar cortex in T2-weighted images (white square). Patient F15-II:1 presented with normal MRI at 5 months, but with severe diffuse atrophy, bilateral symmetrical hyperintensities of thalami and globus pallidus (white square) at 8 months old. In all pictures, MRI pulse sequences (T1, T2, and Flair) and image orientation (S: sagittal, A: axial and C: coronal) are indicated in the upper left corner.</p></caption><graphic xlink:href="41467_2020_14360_Fig1_HTML" id="d29e1815"/></fig></p>
        <p id="Par7">All 30 patients carrying biallelic mutations in <italic>UGDH</italic> presented with a common core phenotype consisting of marked developmental delay, epilepsy, mild dysmorphism, and motor disorder with axial hypotonia (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref> and Suppl. Data&#xA0;<xref rid="MOESM1" ref-type="media">1</xref>). Dysmorphic facial features such as short and flattened philtrum, outward protruding earlobes, ptosis, or blepharophimosis were mild but frequently present (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1b</xref> and Suppl. Data&#xA0;<xref rid="MOESM1" ref-type="media">1</xref>). Most patients have severe epilepsy ranging from neonatal onset developmental epileptic encephalopathy to infantile developmental epileptic encephalopathy (27 patients, 90%), of which 16 (53%) had infantile spasms (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). Three patients have developmental encephalopathy, of which two had seizures in the setting of fever (F5-II:1 and F5-II:2). Only these two patients were seizure-free on sodium valproate. All other patients, except for one patient who seemed to benefit from ketogenic diet, did not respond to antiepileptic treatment. All patients had a severe motor disorder with axial hypotonia, while some patients presented with limb spasticity (43%), dystonia (17%), ataxia, chorea, and tremor, which were often present prior to onset of seizures. Twenty-four out of the 30 (80%) were noted to have swallowing difficulties and gastrostomy tubes were required for feeding in 12 infants. None but two patients (F5-II:1 and II:2) achieved sitting ability. A moderate to severe intellectual disability was observed in all patients. Three patients were deceased between 4 months and 6 years of age (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref> and Suppl. Data&#xA0;<xref rid="MOESM1" ref-type="media">1</xref>). Electroencephalography (EEG) was markedly abnormal with a burst suppression pattern in the neonatal period, hypsarrhythmia in affected children with infantile spasms, and focal and/or generalized spike-wave complexes in childhood (Suppl. Data&#xA0;<xref rid="MOESM1" ref-type="media">1</xref>). MRI revealed a spectrum of abnormalities with delayed myelination and enlarged ventricles probably due to cerebral and cerebellar atrophy in more severely affected patients without any signs of maldevelopment (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1c</xref> and Suppl. Data&#xA0;<xref rid="MOESM1" ref-type="media">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Simplified clinical findings and course of disease in patients with <italic>UGDH</italic> mutations from families F1 to F10.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Family</th><th>Patient</th><th>Gender, age at last follow-up</th><th>Main phenotype</th><th>Age at seizure onset</th><th>Epilepsy, seizure types</th><th>Drug sensitivity</th><th>Motor development at last follow-up</th><th>Intellectual disability</th><th>Speech</th><th>Swallowing/ feeding difficulties</th><th>Hypotonia</th></tr></thead><tbody><tr><td>F1</td><td>II:4</td><td>F, 13&#x2009;yrs</td><td>IDEE</td><td>9 mths</td><td>Epileptic spasms</td><td>Resistant</td><td>Absence</td><td>Severe</td><td>Absence</td><td>Yes, open mouth</td><td>Yes</td></tr><tr><td>F1</td><td>II:6</td><td>M, 5&#x2009;yrs</td><td>IDEE</td><td>15 mths</td><td>Epileptic spasms</td><td>Resistant</td><td>Absence</td><td>Severe</td><td>Absence</td><td>Yes, open mouth drooling</td><td>Yes</td></tr><tr><td>F1</td><td>II:7</td><td>M, 4&#x2009;yrs</td><td>IDEE</td><td>6 mths</td><td>Epileptic spasms</td><td>Resistant</td><td>Absence</td><td>Severe</td><td>Absence</td><td>Yes, open mouth drooling</td><td>Yes</td></tr><tr><td>F2</td><td>II:1</td><td>F, 23 mths</td><td>IDEE</td><td>5 mths</td><td>Epileptic spasms reported back arching directyl after birth</td><td>Resistant</td><td>Absence</td><td>Severe</td><td>ND</td><td>ND</td><td>Yes</td></tr><tr><td>F3</td><td>II:1</td><td>M, 6&#x2009;yrs<sup>a</sup></td><td>IDEE</td><td>8 wks</td><td>Epilepsy with focal seizures, myoclonic jerks, epileptic spasms, status epilepticus</td><td>Resistant</td><td>Absence</td><td>Severe</td><td>Absence</td><td>Yes, g-tube</td><td>Yes</td></tr><tr><td>F3</td><td>II:2</td><td>M, 2&#x2009;yrs</td><td>IDEE</td><td>4 mths</td><td>Epileptic spasms</td><td>Resistant</td><td>Absence</td><td>Severe</td><td>Absence</td><td>Yes, g-tube</td><td>Yes</td></tr><tr><td>F4</td><td>II:1</td><td>M, 5&#x2009;yrs</td><td>IDEE</td><td>4 mths</td><td>Epileptic spasms</td><td>ND</td><td>Absence</td><td>Severe</td><td>Absence</td><td>Yes, g-tube</td><td>Yes</td></tr><tr><td>F5</td><td>II:1</td><td>F, 14 years</td><td>ID, MD</td><td>3&#x2009;yrs</td><td>Seizures in the setting of fever</td><td>Seizure-free on sodium valproate</td><td>Sitting at 12 mths, walking at 3&#x2009;yrs</td><td>Moderate</td><td>Slow acquisition, only single words at 14&#x2009;yrs</td><td>Yes</td><td>Yes</td></tr><tr><td>F5</td><td>II:2</td><td>F, 6&#x2009;yrs</td><td>ID, MD</td><td>3&#x2009;yrs</td><td>Infrequent seizures in the setting of fever</td><td>Seizure-free on sodium valproate</td><td>Sitting unsupported at 23 mths, walking at 3&#x2009;yrs</td><td>Moderate</td><td>First words at 18 mths, simple phrases at 6 yrs</td><td>Yes</td><td>Yes</td></tr><tr><td>F6</td><td>II:1</td><td>M, 4 mths<sup>a</sup></td><td>NDEE</td><td>First day of life</td><td>Epileptic spasms</td><td>ND</td><td>ND</td><td>Severe</td><td>ND</td><td>Yes</td><td>Yes</td></tr><tr><td>F7</td><td>II:1</td><td>M, 7&#x2009;yrs</td><td>IDEE</td><td>14 mths</td><td>Epileptic spasms, gelastic seizures, and other complex partial seizures</td><td>Resistant</td><td>Sitting with support at 14 mths</td><td>Severe</td><td>Absence</td><td>Yes, drooling, g-tube</td><td>Yes</td></tr><tr><td>F8</td><td>II:1</td><td>F, 25 mths</td><td>IDEE</td><td>12 mths</td><td>Epileptic spasms, stimulus-sensitive startles</td><td>Good response to ketogenic diet</td><td>Absence</td><td>Severe</td><td>Absence</td><td>Yes, g-tube</td><td>Yes</td></tr><tr><td>F9</td><td>II:1</td><td>F, 4&#x2009;yrs</td><td>IDEE</td><td>8 wks</td><td>Epileptic spasms, myoclonic seizures, tonic seizures, clonic seizures</td><td>ND</td><td>Absence</td><td>Severe</td><td>Absence</td><td>Yes</td><td>Yes</td></tr><tr><td>F10</td><td>II:1</td><td>F, 5 mths<sup>a</sup></td><td>IDEE, multiple congenital anomalies<sup>b</sup></td><td>4 mths</td><td>Epileptic spasms</td><td>Resistant</td><td>Absence</td><td>Severe</td><td>Absence</td><td>Yes, g-tube</td><td>Yes</td></tr><tr><td>F11</td><td>II:1</td><td>M, 16 mths</td><td>IDEE</td><td>3 mths</td><td>Epileptic spasm, myoclonic seizure, tonic seizure, atonic seizure, clonic seizures</td><td>ND</td><td>Absence</td><td>Severe</td><td>Absence</td><td>Yes, NJ fed</td><td>Yes</td></tr><tr><td>F12</td><td>IV:3</td><td>F, 8 mths</td><td>NDEE</td><td>First day of life</td><td>Postpartum jitteryness, myoclonic jerks, and epileptic spasms</td><td>ND</td><td>ND</td><td>Severe</td><td>ND</td><td>Yes, g-tube</td><td>Yes</td></tr><tr><td>F13</td><td>II:4</td><td>F, 13 mths</td><td>IDEE</td><td>2 mths</td><td>Clusters of epileptic spasms</td><td>Resistant</td><td>Absence</td><td>Severe</td><td>ND</td><td>Yes, g-tube</td><td>Yes</td></tr><tr><td>F14</td><td>II:1</td><td>F, 8&#x2009;yrs</td><td>IDEE</td><td>4 mths</td><td>Segmental and synchronous myoclonus, epileptic spasms in flexion</td><td>Resistant</td><td>Absence</td><td>Severe</td><td>Absence</td><td>Yes, g-tube</td><td>Yes</td></tr><tr><td>F15</td><td>II:1</td><td>F, 8 mths</td><td>IDEE</td><td>4 mths</td><td>Epileptic spasms</td><td>Resistant</td><td>Absence</td><td>Severe</td><td>Absence</td><td>Yes</td><td>Yes</td></tr><tr><td>F16</td><td>II:1</td><td>F, 11&#x2009;yrs</td><td>IDEE</td><td>12 mths</td><td>Daily generalized tonic and myoclonic seizures</td><td>Resistant</td><td>Absence</td><td>Severe</td><td>Absence</td><td>Yes, g-tube</td><td>Yes</td></tr><tr><td>F17</td><td>II:2</td><td>F, 5&#x2009;yrs</td><td>ID, MD</td><td>None</td><td>No epilepsy</td><td>n/a</td><td>Absence</td><td>Severe</td><td>Absence</td><td>No</td><td>Yes</td></tr><tr><td>F18</td><td>II:1</td><td>F, 8&#x2009;yrs</td><td>IDEE</td><td>20 mths</td><td>Daily generalized tonic clonic and later myoclonic seizures with eye fluttering</td><td>Resistant</td><td>Absence</td><td>Severe</td><td>Absence</td><td>No</td><td>Yes</td></tr><tr><td>F19</td><td>II:1</td><td>F, 5&#x2009;yrs</td><td>IDEE</td><td>30 mths</td><td>Recurrent generalized tonic clonic convulsions</td><td>ND</td><td>Absence</td><td>Severe</td><td>Absence</td><td>No</td><td>Yes</td></tr><tr><td>F19</td><td>II:2</td><td>F, 3&#x2009;yrs</td><td>IDEE</td><td>18 mths</td><td>Daily myoclonic seizures with eye fluttering</td><td>ND</td><td>Absence</td><td>Severe</td><td>Absence</td><td>ND</td><td>Yes</td></tr><tr><td>F20</td><td>II:2</td><td>M, 6&#x2009;yrs</td><td>IDEE</td><td>3&#x2009;yrs</td><td>Epileptic spasms,myoclonic seizure, and tonic seizure</td><td>ND</td><td>Absence</td><td>Severe</td><td>Absence</td><td>Yes with difficulty</td><td>Yes</td></tr><tr><td>F21</td><td>II:2</td><td>F,&#xA0;4&#x2009;yrs</td><td>IDEE</td><td>18 mths</td><td>Myoclonic seizure</td><td>ND</td><td>Absence</td><td>Severe</td><td>Absence</td><td>Yes with difficulty</td><td>Yes</td></tr><tr><td>F22</td><td>II:5</td><td>F, 9&#x2009;yrs</td><td>IDEE</td><td>20 mths</td><td>Epileptic spasms</td><td>Resistant</td><td>Absence</td><td>Severe</td><td>Absence</td><td>Yes, NJ fed</td><td>ND</td></tr><tr><td>F23</td><td>II:5</td><td>F,&#xA0;7&#x2009;yrs</td><td>IDEE</td><td>5 mths</td><td>Seizures in the setting of fever</td><td>ND</td><td>ND</td><td>Severe</td><td>Delay</td><td>ND</td><td>Mild</td></tr><tr><td>F24</td><td>II:1</td><td>M, 7&#x2009;yrs</td><td>IDEE</td><td>6 mths</td><td>Myoclonic seizures, generalized tonic clonic seizures</td><td>Resistant</td><td>Absence</td><td>Severe</td><td>Absence</td><td>Yes, g-tube</td><td>Yes</td></tr><tr><td>F25</td><td>II:4</td><td>M, 8&#x2009;yrs</td><td>IDEE</td><td>11 mths</td><td>Myoclonic seizures, generalized tonic clonic seizures</td><td>Resistant</td><td>Absence</td><td>Severe</td><td>Absence</td><td>Yes, g-tube</td><td>Yes</td></tr></tbody></table><table-wrap-foot><p><italic>M</italic> male, <italic>F</italic> female, <italic>IDEE</italic> infantile developmental epileptic encephalopathy, <italic>NDEE</italic> neonatal onset developmental epileptic encephalopathy, <italic>MD</italic> motor disorder, <italic>n/a</italic> not applicable, <italic>ND</italic> non-determined, <italic>ID</italic> intellectual disability, <italic>g-tube</italic> gastrostomy tube, <italic>NJ</italic> nasojejunal, <italic>wks</italic> weeks, <italic>mths</italic> months, <italic>yrs</italic> years.</p><p><sup>a</sup>Age at death.</p><p><sup>b</sup>Multiple congenital anomalies in F16-II:1: prenatal polyhydramnios; multiple ocular anomalies (bilateral cataracts, multiple bilateral lens colobomas, bilateral microphthalmia, hypoplastic iris, iris and lenticular vascularization, bilateral anterior segment dysgenesis, posterior synechiae bilaterally secondary to neovascularization); megacystis; neurogenic bladder; moderate hiatal hernia; camptodactyly of 3rd and 4th fingers and overriding 2nd and 4th digits on the right hand; long tapered fingers; skeletal survey showed overlapping of the parietal bones and mild elongation of the 2nd through 5th fingers.</p></table-wrap-foot></table-wrap></p>
      </sec>
      <sec id="Sec4">
        <title><italic>UGDH</italic> mutations behave as hypomorphic alleles</title>
        <p id="Par8">The UGDH oxidoreductase consists of three distinct domains<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>: the NAD-binding (N-terminal) and UDP-binding (C-terminal) domains, and an internal domain that bridges the two termini together<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>. The UGDH enzyme assembles into a disc-shaped double layer composed of a trimer of dimers<sup><xref ref-type="bibr" rid="CR6">6</xref></sup> (Suppl. Fig.&#xA0;<xref rid="MOESM1" ref-type="media">2a, b</xref>). This hexameric structure is a prerequisite for proper UGDH enzymatic function<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. The 23 germline mutations presented in this study are distributed throughout the <italic>UGDH</italic> gene and its encoded protein (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2a</xref>). One of the variants in Family 12 mutates the first nucleotide of exon 8 (c.907&#x2009;G&#x2009;&gt;&#x2009;A; p.Val303Ile, Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2a, b</xref>), which is predicted to affect the splice donor site<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. Three different nonsense mutations were found in a compound heterozygous state with a missense mutation (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2a</xref> and Suppl. Table&#xA0;<xref rid="MOESM1" ref-type="media">2</xref>). All identified missense mutations are anticipated to be destabilizing according to DUET<sup><xref ref-type="bibr" rid="CR17">17</xref></sup> (Suppl. Table&#xA0;<xref rid="MOESM1" ref-type="media">2</xref>, &#x394;&#x394;G). The missense mutations in residues Y14, I42 and A44, which are close to the NAD-binding site (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2c</xref> and Suppl. Fig.&#xA0;<xref rid="MOESM1" ref-type="media">2c</xref>) are expected to impair NAD<sup>+</sup> reduction. Alteration of residues in the central domain such as I255, G271, M306, and R317 are expected to affect homo-dimerization<sup><xref ref-type="bibr" rid="CR18">18</xref></sup> (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2b</xref> and Suppl. Fig.&#xA0;<xref rid="MOESM1" ref-type="media">2d</xref>). The I116 residue (located in the NAD-binding domain), as well as the R393 and A410 residues (UDP-Glc binding domain) sit at the dimer-dimer interface<sup><xref ref-type="bibr" rid="CR19">19</xref></sup> (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2d</xref>), suggesting that these variants may prevent UGDH from assembling into a functional hexameric enzyme.<fig id="Fig2"><label>Fig. 2</label><caption><title>Mutations in UGDH enzyme possibly affect critical amino-acids.</title><p><bold>a</bold>
<italic>UGDH</italic> genomic and protein domain structures. Type and positions of 22 germline <italic>UGDH</italic> mutations. 5&#x2032; and 3&#x2032; UTRs are shown in dark gray. NAD-binding (blue), central (pink), and UDP-binding (orange) domains are highlighted. Homozygous mutations are shown in bold. Compound heterozygous mutations that are in trans are linked by a line below the UGDH domain structure. <bold>b</bold>&#x2013;<bold>d</bold> Three close-up views ribbon diagrams of the UGDH protein bound to UDP-Glc and NADH. <bold>b</bold> Interface between the central domains of subunits A and B. <bold>c</bold> NAD-binding site in NAD-binding domain of subunit A. Distances between NADH and mutated residues in patients are measured in Angstr&#xF6;m (&#xC5;). <bold>d</bold> Interface between the subunit A NAD-binding domain with the subunit C UDP-Glc-binding domain. In all the structures, residues carrying missense mutations in the patients are highlighted as 3D backbone. Residues Q110 and T325 known to interact together for dimer formation<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>; and residue V132, which is important for hexamerization<sup><xref ref-type="bibr" rid="CR15">15</xref></sup> are highlighted in black backbone. In all the structures, NAD-binding (blue), central (light/dark pink), and UDP-binding (orange) domains are shown. UDP-Glc (dark red) and NADH (midnight blue) are represented as colored carbon backbones. Adapted from PDB code 2Q3E<sup><xref ref-type="bibr" rid="CR6">6</xref></sup> using the Swiss-Pdb Viewer software<sup><xref ref-type="bibr" rid="CR67">67</xref></sup>. For gels and graphs source data, please refer to the source data files 1 and 2.</p></caption><graphic xlink:href="41467_2020_14360_Fig2_HTML" id="d29e3249"/></fig></p>
        <p id="Par9">To better understand the effect of the mutations on UGDH, we then derived and biobanked primary dermal fibroblasts from patients F3-II:1 (R393W/A410S), F4-II:1 (Y14C/S72P), F5-II:1 (A82T/A82T) and F6-II:1 (R65*/Y367C), and a non-affected parent F5-I:1 (WT/A82T). Endogenous <italic>UGDH</italic> messenger RNA (mRNA) levels were not significantly different in patients&#x2019; primary cells as compared to control fibroblasts (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3a</xref>, top panels). In contrast, we observed significant changes in endogenous UGDH protein levels for three of the four alleles studied. Fibroblasts with compound heterozygous R393W/A410S mutations displayed comparable UGDH levels relative to wild-type (WT) cells, while patients&#x2019; cells with R65*/Y367C, Y14C/S72P, or homozygous A82T mutations showed dramatically reduced endogenous UGDH levels (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3a</xref>, bottom panels). In contrast to the three nonsense mutations and the missense mutation potentially affecting splicing, which are likely to cause nonsense-mediated decay of the endogenous <italic>UGDH</italic> transcript, the missense mutations are most likely impacting the stability of the enzyme and/or its oxidoreductase activity. Consistently, we observed a significant decrease in the UGDH-catalyzed reduction of NAD<sup>+</sup> to NADH in patients&#x2019; primary fibroblasts (R393W/A410S, Y14C/S72P, or homozygous A82T mutations) while the non-affected parent&#x2019;s cells heterozygous for the A82T mutation showed intermediate level of NAD<sup>+</sup> reduction (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3b</xref>, left panels). Patient&#x2019;s cells with the homozygous A82T mutation also exhibited a reduction in the synthesis of hyaluronic acid (HA), which requires UDP-glucuronate, a product of UGDH enzymatic activity (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3b</xref>, right panel). When produced in bacteria, mutant UGDH had altered stability, kinetic, and biochemical properties as compared to WT-UGDH. Compared to the wild-type enzyme, mutant A44V and A82T UGDH (mutations found at the homozygous state in the patients from Families 1 and 5, respectively) were more susceptible to partial proteolysis by trypsin (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3c</xref>). The stability of UGDH<sup>A44V</sup> could be partially rescued upon incubation with substrate, product, or cofactor, while the UGDH<sup>A82T</sup> remained strongly sensitive to proteolysis regardless of the presence of any cofactor or substrate (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3c</xref>). A thermal stability study showed that the melting temperature of UGDH<sup>A44V</sup> was significantly reduced relative to WT and could only partially be rescued upon addition of substrate, product, reduced or oxidized cofactor, or any combination thereof (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3d</xref>). Notably, UGDH<sup>A82T</sup> was so intrinsically unstable that a melting temperature was unable to be ascertained. By gel filtration chromatography, we investigated the effect of the A44V and A82T mutations on UGDH oligomerization. When compared to UGDH<sup>WT</sup>, UGDH<sup>&#x2206;132</sup> (an obligate hexamer<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>), and UGDH<sup>T325D</sup> (an obligate dimer<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>), we observed that UGDH<sup>A44V</sup> and UGDH<sup>A82T</sup> proteins were mainly eluted as dimer and monomer species, respectively, with virtually no stable hexameric population (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3e</xref>). This suggests that the A44V and A82T mutations may affect UGDH function by altering its capacity to form active hexamers. Finally, using equal amounts of recombinant enzyme, we determined that UGDH<sup>A44V</sup> and UGDH<sup>A82T</sup> were respectively 75 and 50% less efficient at reducing NAD<sup>+</sup> to NADH as compared to UGDH<sup>WT</sup> (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3f</xref>). Similarly, comparison of the steady state Michaelis&#x2013;Menten kinetic constants (summarized in Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref>) showed that UGDH<sup>A44V</sup>
<italic>V</italic><sub>max</sub> was only&#x2009;~&#x2009;50% of the value of UGDH<sup>WT</sup> for both cofactor and substrate. In contrast, <italic>K</italic><sub>m</sub> was not significantly different from UGDH<sup>WT</sup> for either cofactor or substrate, revealing that the mutation results in a reduced ability of the enzyme to catalyze the reaction, while still being able to associate with NAD<sup>+</sup> and UDP-Glc. Taken together, our biochemical findings indicate that these missense mutations mainly impact the enzymatic function of UGDH by altering its quaternary structure and/or directly impairing its oxidoreductive activity.<fig id="Fig3"><label>Fig. 3</label><caption><title>Biallelic UGDH mutations behave as hypomorphic alleles.</title><p><bold>a</bold> RT-qPCR (top), western blotting (bottom), and <bold>b</bold> enzymatic activity, assessed by measuring NADH production (left panel) and quantification of HA (right panel), for endogenous UGDH using patient-derived primary fibroblasts. <bold>a</bold>, <bold>b</bold> Control (WT/WT), unaffected mother F5-I:1 (WT/A82T) and 4 (in <bold>a</bold>) or 3 (in <bold>b</bold>) different patients&#x2019; fibroblasts (F5-II:1: A82T/A82T, F3-II:1: R393W/A410S, F4-II:1: Y14C/S72P, and F6-II:1: R65*/Y367C). <bold>a</bold> (top) Endogenous <italic>UGDH</italic> mRNA levels are normalized to <italic>&#x3B2;-ACTIN</italic> and <italic>GAPDH</italic>. Fold change relative to control (WT/WT) is plotted. <bold>a</bold> (bottom) Western blot analysis for endogenous UGDH protein using cellular extracts. GAPDH is used as a loading control. <bold>b</bold> (left) UGDH enzymatic activity measured as the conversion of NAD<sup>+</sup> to NADH in whole-cell lysates. <bold>b</bold> (right) UGDH enzymatic activity measured as the HA production in conditioned media from primary fibroblast cultures. <bold>c</bold> Western blot analysis for UGDH sensitivity to limited proteolysis using purified WT and mutant (A44V and A82T) UGDH proteins in the absence or presence of its substrates and/or cofactors, as indicated. Results are representative of at least three experimental replicates. <bold>d</bold> Purified UGDH WT and A44V melting temperature (Tm) in the absence or presence of its substrates and/or cofactors, as indicated. Mean of three experiments&#x2009;&#xB1;&#x2009;S.D. is plotted for the <italic>T</italic><sub>m</sub> of each enzyme. <bold>e</bold> Representative traces at <italic>&#x3BB;</italic>&#x2009;=&#x2009;280&#x2009;nm of purified WT and mutant UGDH proteins fractionated by size exclusion chromatography. WT, obligate dimer &#x2206;132<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>, obligate hexamer T325D<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>, A44V and A82T UGDH are plotted in the graph. Dashed lines correspond to the known hexamer, dimer and monomer peak elution times. <bold>f</bold> Purified WT, A44V, and A82T UGDH enzymatic activity measured as the conversion of NAD&#x2009;+&#x2009;to NADH. Asterisks indicate <italic>p</italic>-values of <italic>p</italic>&#x2009;&lt;&#x2009;0.05(*), <italic>p</italic>&#x2009;&lt;&#x2009;0.01(**), and <italic>p</italic>&#x2009;&lt;&#x2009;0.001(***), NS: non-significant (<italic>p</italic>&#x2009;&gt;&#x2009;0.05) as determined by Student <italic>t</italic>-test. For gels and graphs source data, please refer to the source data files 1 and 2.</p></caption><graphic xlink:href="41467_2020_14360_Fig3_HTML" id="d29e3470"/></fig><table-wrap id="Tab2"><label>Table 2</label><caption><p>Summary of WT and mutant UGDH kinetic constants.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th><italic>K</italic><sub>m</sub> (&#xB5;M)</th><th><italic>V</italic><sub>max</sub> (nmol/min/mg)</th></tr></thead><tbody><tr><td colspan="3">UDP-glucose</td></tr><tr><td>&#x2003;WT</td><td>28.6&#x2009;&#xB1;&#x2009;6.8</td><td>235.6&#x2009;&#xB1;&#x2009;12.5</td></tr><tr><td>&#x2003;A44V</td><td>15.9&#x2009;&#xB1;&#x2009;2.3*</td><td>118.3&#x2009;&#xB1;&#x2009;3.3***</td></tr><tr><td>&#x2003;A82T</td><td>ND</td><td>ND</td></tr><tr><td>NAD+</td><td/><td/></tr><tr><td>&#x2003;WT</td><td>401&#x2009;&#xB1;&#x2009;75</td><td>219.2&#x2009;&#xB1;&#x2009;11.2</td></tr><tr><td>&#x2003;A44V</td><td>316&#x2009;&#xB1;&#x2009;54 NS</td><td>109.4&#x2009;&#xB1;&#x2009;4.5***</td></tr><tr><td>&#x2003;A82T</td><td>ND</td><td>ND</td></tr></tbody></table><table-wrap-foot><p>Steady state rate constants for UGDH<sup>WT</sup> and UGDH<sup>A44V</sup> were determined by varying UDP-glucose or NAD<sup>+</sup> independently and fitting to the Michaelis&#x2013;Menten equation. UGDH<sup>A82T</sup> steady state constants could not be determined. Values indicate mean&#x2009;&#xB1;&#x2009;SD of triplicate assays. Asterisks indicate <italic>p</italic>-values of <italic>p</italic>&#x2009;&lt;&#x2009;0.05(*) and <italic>p</italic>&#x2009;&lt;&#x2009;0.001(***), NS: non-significant (<italic>p</italic>&#x2009;&gt;&#x2009;0.05) as determined by Student <italic>t-</italic>test. ND: not determined.</p></table-wrap-foot></table-wrap></p>
      </sec>
      <sec id="Sec5">
        <title>Patient-derived cerebral organoids partially phenocopy human disease</title>
        <p id="Par10">Our attempts to model this developmental epileptic encephalopathy using the existing zebrafish hypomorphic loss-of-function <italic>ugdh</italic> (c.992&#x2009;T&#x2009;&gt;&#x2009;A; p.I331D) allele known as <italic>jekyll m151</italic><sup><xref ref-type="bibr" rid="CR20">20</xref>&#x2013;<xref ref-type="bibr" rid="CR22">22</xref></sup> were unsuccessful (Suppl. Fig.&#xA0;<xref rid="MOESM1" ref-type="media">3</xref>). The behavioral activity of homozygous <italic>jekyll</italic> mutant larvae were recorded in presence or absence of the seizure-inducing drug pentylenetetrazol (PTZ)<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>. By quantitative PCR (qPCR), <italic>c-fos</italic> expression, which marks neural activity<sup><xref ref-type="bibr" rid="CR23">23</xref>,<xref ref-type="bibr" rid="CR24">24</xref></sup>, similarly increased in a dose-dependent manner upon PTZ treatment in all larvae regardless of genotypes (Suppl. Fig.&#xA0;<xref rid="MOESM1" ref-type="media">3a&#x2013;d</xref>). Homozygous mutant larvae did not show signs of increased <italic>c-fos</italic> expression at basal state, suggesting that fish depleted of Ugdh activity do not exhibit spontaneous seizure and are equally responsive to PTZ treatment. As noted by reviewers, <italic>ugdh</italic> mutant fish do not have fully-inflated swim bladders, which may contribute to their reduced locomotor activity and demise before 14-dpf (Suppl. Fig.&#xA0;<xref rid="MOESM1" ref-type="media">3e</xref>). These in vivo experiments suggest that zygotic <italic>ugdh</italic> depletion in zebrafish does not satisfactorily model the human disease.</p>
        <p id="Par11">UGDH has been extensively studied in vertebrate model organisms where its complete knockout causes embryonic lethality around gastrulation<sup><xref ref-type="bibr" rid="CR25">25</xref>,<xref ref-type="bibr" rid="CR26">26</xref></sup>. To address its role in the context of central nervous system (CNS) development in humans, we attempted instead to model this disease in vitro by developing cerebral organoids<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR28">28</xref></sup> from several patients with compound heterozygous R65*/Y367C, Y14C/S72P or homozygous A82T mutations, and from a non-affected parent (WT/A82T). After 10 weeks of differentiation, the volume of cerebral organoids from patients with biallelic <italic>UGDH</italic> mutations was on average 50% smaller and showed rougher edges than that of WT or carrier WT/A82T cerebral organoids (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4a, b</xref> and Suppl. Fig.&#xA0;<xref rid="MOESM1" ref-type="media">4a</xref>). Quantitative reverse transcription PCR (RT-qPCR) analysis revealed decreased levels of the early and intermediate neuronal progenitors markers <italic>PAX6</italic> and <italic>TBR2</italic>, respectively, while the levels of neuronal marker <italic>TUJ1</italic> were unchanged (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4c</xref> and Suppl. Fig.&#xA0;<xref rid="MOESM1" ref-type="media">4b</xref>). Immunofluorescence revealed similar amounts of peripheral neurons marked by TUJ1, and astrocytes marked by GFAP while ventricular zones marked by SOX2-positive neuronal progenitors were appreciably less proliferative. This was evidenced by reduced PCNA staining in mutant cerebral organoids relative to WT and WT/A82T sections (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4d</xref> and Suppl. Fig.&#xA0;<xref rid="MOESM1" ref-type="media">4c</xref>). These results argue that reduced UGDH activity is associated with impaired neuronal development in vitro, causing atrophy of patient-derived cerebral organoids. Even though our cerebral organoid data is congruent with our patients&#x2019; phenotype and biochemistry data, replicative studies with additional WT and complete UGDH knockout lines are warranted in light of the known variability in induced pluripotent stem cells (iPSCs&#x2019;) response to differentiation protocols.<fig id="Fig4"><label>Fig. 4</label><caption><title>Patient-derived cerebral organoids are underdeveloped.</title><p><bold>a</bold> Volumes (mean&#x2009;&#xB1;&#x2009;SD) and <bold>b</bold> representative images (scale bar&#x2009;=&#x2009;1&#x2009;mm) of cerebral organoids derived from iPSCs from WT (<italic>n</italic>&#x2009;=&#x2009;18 organoids from the same batch), unaffected parent (<italic>UGDH</italic> WT/A82T, <italic>n</italic>&#x2009;=&#x2009;15), and patients (<italic>UGDH</italic> A82T/A82T (<italic>n</italic>&#x2009;=&#x2009;10), Y14C/S72P (<italic>n</italic>&#x2009;=&#x2009;7), and R65*/Y367C (<italic>n</italic>&#x2009;=&#x2009;6) after 10 weeks of differentiation. Lower right panel: close-up views of the edges of indicated cerebral organoids. Scale bar&#x2009;=&#x2009;500&#x2009;&#x3BC;m. <bold>c</bold> RT-qPCR for neuronal differentiation markers (<italic>PAX6</italic>, <italic>TBR2</italic>, and <italic>TUJ1</italic>) in WT (<italic>n</italic>&#x2009;=&#x2009;4 cerebral organoids), unaffected parent (WT/A82T, <italic>n</italic>&#x2009;=&#x2009;3), and patients (A82T/A82T, Y14C/S72P, and R65*/Y367C, <italic>n</italic>&#x2009;=&#x2009;3 each) cerebral organoids. Levels of expression are normalized to <italic>GAPDH</italic>. Mean&#x2009;&#xB1;&#x2009;SD fold change relative to WT is plotted. <bold>d</bold> Representative images of consecutive sections of cerebral organoids derived from iPSCs from WT (<italic>N</italic>&#x2009;=&#x2009;5 cerebral organoids, <italic>n</italic>&#x2009;=&#x2009;40 ventricle-like zones), unaffected parent (WT/A82T, <italic>N</italic>&#x2009;=&#x2009;4, <italic>n</italic>&#x2009;=&#x2009;15), and patients (A82T/A82T <italic>N</italic>&#x2009;=&#x2009;3, <italic>n</italic>&#x2009;=&#x2009;40, Y14C/S72P <italic>N</italic>&#x2009;=&#x2009;4, <italic>n</italic>&#x2009;=&#x2009;18, and R65*/Y367C <italic>N</italic>&#x2009;=&#x2009;2, <italic>n</italic>&#x2009;=&#x2009;9) stained with H&amp;E, and immunostained with markers TUJ1/PCNA/DAPI, SOX2/DAPI, and GFAP/DAPI. Scale bar&#x2009;=&#x2009;100&#x2009;&#x3BC;m. <bold>a</bold>, <bold>c</bold> Asterisks indicate <italic>p</italic>-values of <italic>p</italic>&#x2009;&lt;&#x2009;0.05(*), <italic>p</italic>&#x2009;&lt;&#x2009;0.001(***), NS: non-significant (<italic>p</italic>&#x2009;&gt;&#x2009;0.05) as determined by ANOVA test with Bonferroni correction. <bold>a</bold>&#x2013;<bold>c</bold> Cerebral organoids represented here are all from batch 2 and derived from iPSCs clone 1 for each genotype, see Suppl. Fig.&#xA0;<xref rid="MOESM1" ref-type="media">4</xref> for more information. For graphs source data, please refer to the source data file 2.</p></caption><graphic xlink:href="41467_2020_14360_Fig4_HTML" id="d29e3829"/></fig></p>
        <p id="Par12">To understand whether mutations in <italic>UGDH</italic> directly affect neuronal function, we also differentiated WT, non-affected parent (WT/A82T), and patient (Y14C/S72P) iPSCs into neuro-precursor cells (NPCs), which were subsequently matured into neurons over a period of 21 days. Using a multi-electrode array (MEA) system, and in contrast to neurons mutant for <italic>CAMK2A</italic><sup><xref ref-type="bibr" rid="CR29">29</xref></sup>, no significant differences between controls and mutant <italic>UGDH</italic> neurons were recorded for either the total number of spontaneous spikes or the mean firing rate (Suppl. Fig.&#xA0;<xref rid="MOESM1" ref-type="media">4d</xref>). Altogether, these in vitro experiments suggest that while UGDH is not required for proper function of isolated neurons in culture, its absence significantly affects neuronal differentiation in cerebral organoids, which may provide a powerful platform to study the pathogenesis for the new disease in vitro.</p>
      </sec>
    </sec>
    <sec id="Sec6" sec-type="discussion">
      <title>Discussion</title>
      <p id="Par13">In this study, we described disease-causing mutations in <italic>UGDH</italic> in humans. These 23 coding variants represent an allelic series of germline mutations, which when inherited recessively are responsible for epileptic encephalopathy with variable degrees of developmental delay. We propose to name this novel Mendelian disease Jamuar Syndrome, a member of the early infantile epileptic encephalopathies (EIEE). The genetic, biochemical, cellular and developmental findings reveal that these <italic>UGDH</italic> germline mutations behave as loss-of-function alleles. This was confirmed in vitro using patient-derived cerebral organoids, which showed marked underdevelopment. In zebrafish, we found that hypomorphic <italic>ugdh</italic><sup><italic>I331D</italic><italic>/</italic><italic>I331D</italic></sup> mutant larvae did not show signs of increased seizures at baseline or after PTZ treatment. The brain-specific <italic>UGDH</italic> phenotype in humans may come as a surprise since in <italic>Drosophila</italic>, zebrafish, and mouse, complete knockout of <italic>Ugdh</italic> cause early and lethal gastrulation defects by hindering FGF signaling<sup><xref ref-type="bibr" rid="CR25">25</xref>,<xref ref-type="bibr" rid="CR30">30</xref>&#x2013;<xref ref-type="bibr" rid="CR32">32</xref></sup>. One potential explanation for this incongruity is that other proteoglycans not reliant on UGDH activity for the synthesis of UDP-GlcA or UDP-Xylose (UDP-Xyl) may be solicited and help bypass the need for UGDH during human gastrulation. Alternatively, a complete knockout of UGDH in humans may not be viable as we did not identify any homozygous or compound heterozygous truncating mutations. A search in ExAC for homozygous variants resulted in mostly synonymous or non-coding variants. Only two homozygous missense variants were detected, but no homozygous truncating mutations were seen (Suppl. Table&#xA0;<xref rid="MOESM1" ref-type="media">3</xref>). This suggests that the severity of the epileptic encephalopathy may correlate with the amount of residual UGDH activity, the extent of which may be sufficient to allow gastrulation to take place during early human embryonic stages but may be limiting for neuronal development thereafter.</p>
      <p id="Par14">As UDP-GlcA is the major product of the UGDH enzyme, it is possible that reduced levels of UDP-GlcA may trigger a cascade of secondary pathogenic events resulting in neurodevelopmental delay and encephalopathy. In support of this, is the recent demonstration that a homozygous loss-of-function mutation in the upstream enzyme UGP2 is also responsible for a severe form of developmental epileptic encephalopathy in humans<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>. UDP-GlcA is not only needed for detoxification via glucuronidation, but is also a key component of glycosaminoglycans (GAGs). UGDH deficiency might parralel other neurological diseases with defects in GAG synthesis, modification, and degradation. For example, <italic>EXTL3</italic> and <italic>CHSY1</italic> mutations, which affect heparan sulfate and chondroitin sulfate synthesis, respectively, cause developmental delay and intellectual disabilities<sup><xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR35">35</xref></sup>. Defects in heparan sulfate modification caused by <italic>NDST1</italic> mutations are responsible for intellectual disability associated with epilepsy<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>. Moreover, mucopolysaccaridoses, diseases caused by defects in GAG degradation, affect cognitive development<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>. In addition, proteoglycans containing GlcA derived from UDP-GlcA are major components of the extracellular matrix (ECM) and key players in neuronal development and plasticity<sup><xref ref-type="bibr" rid="CR38">38</xref></sup>, particularly in areas important for neuronal migration<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>. In human, various psychiatric and intellectual disorders are caused by mutations in genes involved in ECM homeostasis and may be driven by neuronal migration defects<sup><xref ref-type="bibr" rid="CR38">38</xref></sup>. The central role of UDP-GlcA may open a window for early therapeutic interventions. In plants and lower animals, including zebrafish, UDP-GlcA can be synthesized by two alternative pathways. Apart from UGDH, UDP-GlcA can be generated via the myo-inositol oxygenation pathway from glucuronic acid by glucuronokinase and UDP-glucuronic acid pyrophosphorylase<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>. If a similar route exists in humans, supplementation of glucuronate may help to enhance this alternative pathway and increase levels of UDP-GlcA levels and its essential metabolites. To this date, however, the existence of human homologs of glucuronokinase and UDP-glucuronic acid pyrophosphorylase remains to be proven.</p>
      <p id="Par15">Conservative estimates of disease frequency resulting from germline <italic>UGDH</italic> mutations projects a prevalence of 1:14,000,000 to 1:2,000,000 (Suppl. Note&#xA0;<xref rid="MOESM1" ref-type="media">1</xref>). Considering that developmental epileptic encephalopathies are most commonly caused by de novo dominant mutations, this estimated prevalence seems relatively frequent.</p>
    </sec>
    <sec id="Sec7">
      <title>Methods</title>
      <sec id="Sec8">
        <title>Ethical approval</title>
        <p id="Par16">Written informed consent was obtained from the parents of the underage patients for diagnostic procedures and next-generation sequencing, as well as for the publication of identifying facial images in Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1b</xref>. The study has been approved by the local Institutional Review Board of the Medical Faculty of the University of T&#xFC;bingen, Germany (vote 180/2010BO1).</p>
      </sec>
      <sec id="Sec9">
        <title>Exome sequencing</title>
        <p id="Par17">To unravel the molecular cause of the disease exome sequencing were performed at different genetic institutes using next-generation sequencing techniques according to local standard protocols. Variants were confirmed via Sanger sequencing using standard methods and chemicals (primer sequences are available on request).</p>
        <p id="Par18"><italic>Family 1</italic>: Exome sequencing for two affected siblings was performed on a HiSeq2500 System (Illumina, CA) after enrichment with SureSelectXT Human All Exon V5 (Agilent, Santa Clara CA). FASTQ files were imported into GENESIS (<ext-link ext-link-type="uri" xlink:href="http://thegenesisprojectfoundation.org/">http://thegenesisprojectfoundation.org/</ext-link>)<sup><xref ref-type="bibr" rid="CR12">12</xref></sup> for further analysis using a pipeline build on BWA<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>, Picard, and FreeBayes. Variants were filtered for changes that segregated in an autosomal recessive fashion and passed the following filter criteria: (i) frequency in public databases (ExAC<sup><xref ref-type="bibr" rid="CR10">10</xref></sup> minor allele frequency (MAF)&#x2009;&lt;0.1%), (ii) present in &lt;5 families within GENESIS (&#x2009;&#x223C;&#x2009;4,300 exomes), (iii) conserved (PhyloP 100-way score&#x2009;&gt;2 or PhastCons (100 vertebrate genomes)&#x2009;&gt;0.75), (iv) CADD score&#x2009;&gt;12, and (v) sufficient quality scores (Genotype Quality&#x2009;&gt;75). In addition, variants had to be present in exomes from both siblings. This resulted in a list of seven variants (Suppl. Table&#xA0;<xref rid="MOESM1" ref-type="media">1</xref>), out of which only the homozygous missense variant c.131&#x2009;C&#x2009;&gt;&#x2009;T in the <italic>UGDH</italic> gene segregated with the third affected sibling.</p>
        <p id="Par19"><italic>Families 2, 9, 10</italic>: Using genomic DNA from the proband and parents, the exonic regions and flanking splice junctions of the genome were captured using the Agilent SureSelect Human All Exon V4 (50&#x2009;Mb) or the Clinical Research Exome kit (Agilent Technologies, Santa Clara, CA). Massively parallel (NextGen) sequencing was done on an Illumina system with 100&#x2009;bp or greater paired-end reads. Reads were aligned to human genome build GRCh37/UCSC hg19, and analyzed for sequence variants using a custom-developed analysis tool. Additional sequencing technology and variant interpretation protocol has been previously described<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>. The general assertion criteria for variant classification are publicly available on the GeneDx ClinVar submission page (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/clinvar/submitters/26957/">http://www.ncbi.nlm.nih.gov/clinvar/submitters/26957/</ext-link>). After variant stratification based on population frequencies within an internal database and ExAC<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>, inheritance, in silico predictors such as Provean, Mutation Taster and CADD, GeneDX reported only the UGDH variants to be the best potentially pathogenic candidates and connected to this project via GeneMatcher entries.</p>
        <p id="Par20"><italic>Family 3</italic>: Samples of the oldest sibling and both parents were sequenced in context of the EUROCORES project EuroEPINOMICS-RES, for which the technical details have been reported before<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>. Briefly, the trio underwent exome sequencing at the Wellcome Trust Sanger Institute (Hinxton/Cambridge, UK). Capturing of the exome was performed using the SureSelect Human All Exon 50&#x2009;Mb exome kit (Agilent). The enriched exome libraries were then sequenced on a HiSeq2000 platform (Illumina) as 75&#x2009;bp paired-end reads. BWA was used to align the sequenced reads to the reference genome (hg19). De novo analysis of these data did not reveal any variants. As the younger sib later developed a similar disorder, exome sequencing was also performed locally on the second sibling: for library preparation, genomic DNA was sheared to the average size 150&#x2009;bp (Covaris) and the genome libraries prepared using KAPA HTP Lib Prep Kit Illumina 96 rxns (07138008001). Exome capturing was performed using the SeqCap EZ Human Exome v3.0 capture system and the sample was sequenced on the NextSeq500 platform using NextSeq500 High-output V2 kit. Mapping to the human reference genome (Hg19) and variant calling were performed with the CLC Genomics Workbench. Subsequent annotation and filtering were executed with GenomeComb<sup><xref ref-type="bibr" rid="CR44">44</xref></sup> (<ext-link ext-link-type="uri" xlink:href="http://genomecomb.sourceforge.net/">http://genomecomb.sourceforge.net/</ext-link>). Exome sequencing results of the trio and the second sibling were merged and reannotated and the family was reanalyzed as a quartet. Variants were filtered based on following quality parameters: coverage&#x2009;&gt;7, quality&#x2009;&gt;50 and not located in homopolymers&#x2009;&gt;8 or tandem repeats. Only variants present with a frequency&#x2009;&lt;0.5% in control population databases ExAC<sup><xref ref-type="bibr" rid="CR10">10</xref></sup> and Exome Variant Server, seen&#x2009;&lt;3 times in the local exome sequencing database, and with predicted impact on the encoded protein (missense, nonsense, frameshift, deletions, insertions and (essential) splice site) were retained for further analysis. Remaining variants were filtered under an autosomal recessive (homozygous or compound heterozygous) and x-linked hypothesis. In addition, heterozygous variants called in both siblings and absent in the parents were selected under a parental mosaics for which the ExAC<sup><xref ref-type="bibr" rid="CR10">10</xref></sup> filter was set at&#x2009;&lt;2 calls. This analysis revealed only this one compound heterozygous <italic>UGDH</italic> variants.</p>
        <p id="Par21"><italic>Family 4</italic>: Parent-proband trio exomes were prepared using the SureSelect Target Enrichment System (Agilent, Santa Clara CA) and sequenced on a HiSeq2000 System (Illumina, CA). Data processing, bioinformatics pipeline (for alignment, variant calling, annotation, and genetic model filtering), and analyses were previously described<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>. The compound heterozygous rare missense alterations in the <italic>UGDH</italic> gene, c.214T&#x2009;&gt;&#x2009;C and c.41A&#x2009;&gt;&#x2009;G, were interpreted as the only candidate genetic etiology.</p>
        <p id="Par22"><italic>Family 5</italic>: The exome library was prepared on an ION OneTouch System and sequenced on an Ion Proton instrument (Life Technologies, Carlsbad, CA, USA) using one ION PI chip. Sequence reads were aligned to the human GRCh37/hg19. Variants were filtered for common SNPs using the NCBI&#x2019;s &#x201C;common and no known medical impacts&#x201D; database (ClinVar), ExAC<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>, as well as an in-house database of 406 sequenced samples. Additional filters were applied to retain proband&#x2019;s exonic variants that were homozygous while heterozygous in both parents. Out of 5 homozygous variants, only one missense variant c.244G&#x2009;&gt;&#x2009;A in the <italic>UGDH</italic> gene was found to segregate with the disease.</p>
        <p id="Par23"><italic>Family 6</italic>: Exome sequencing was performed on a NextSeq 500 System (Illumina, CA USA), with a 2&#x2009;&#xD7;&#x2009;150&#x2009;bp high-output sequencing kit after enrichment with Seq Cap EZ MedExome kit (Roche, Basel Switzerland). Sequence alignment, variant calling, and variant annotation was performed by Genosplice Technology (Paris France) with BWA 0.7.12, picard-tools-1.121, GenomeAnalysisTK-2014.3-17-g0583018 and SNPEff-4.2 with additional annotations from ClinVar and HGMD. The compound heterozygous <italic>UGDH</italic> variants were selected to be the most promising candidates and were thus submitted to GeneMatcher.</p>
        <p id="Par24"><italic>Families 7, 8, 16&#x2013;25</italic>: Exome sequencing was performed essentially as described before<sup><xref ref-type="bibr" rid="CR46">46</xref></sup> for families 7, 8, and 16&#x2013;25. Target regions were enriched using the Agilent SureSelectXT Human All Exon 50&#x2009;Mb Kit. Whole-exome sequencing was performed on the Illumina HiSeq platform (BGI, Copenhagen, Denmark) followed by data processing with BWA (read alignment,) and GATK (variant calling) software packages. Variants were annotated using an in-house developed pipeline. Prioritization of variants was done by an in-house designed &#x201C;variant interface&#x201D; and manual curation. As four families with similar phenotype shared the homozygous p.R317Q as best candidate, a GeneMatcher entry was made and the in-house database was systematically screened for other potentially pathogenic <italic>UGDH</italic> variants. This allowed the identification of families 18 to 25.</p>
        <p id="Par25"><italic>Family 11</italic>: The sequencing was performed at Claritas Genomics (Cambridge, USA). Extracted genomic DNA was amplified using the AmpliSeq system and sequenced using an IonTorrent Proton Instrument. Alignment and variant calling of the nuclear DNA was done on Proton data using Torrent Suite 4.4 Software. Nuclear variants were filtered for quality using a custom filtering tool. In addition, extracted genomic and mitochondrial DNA was also run on an Agilent Clinical Research Exome capture sequence and then sequenced using an Illumina NextSeq instrument. Alignment and variant calling on NextSeq data was performed by an implementation of GATK Best Practices Pipeline. Genomic DNA results from the two NGS runs on the proband were combined and annotated by a custom bioinformatics pipeline. Besides a heterozygous <italic>SLC6A5</italic> missense variant inherited from the unaffected father, the compound heterozygous <italic>UGDH</italic> variants were the only candidates reported that had a minor allele frequency (MAF) of&#x2009;&lt;&#x2009;or&#x2009;=&#x2009;0.01% that passed the laboratory&#x2019;s quality metrics and were not de novo, X-linked or had biallelic variants.</p>
        <p id="Par26"><italic>Family 12</italic>: Isolated genomic DNA from peripheral blood leukocytes of proband and parents was captured with the Agilent Sure Select Clinical Research Exome (CRE) kit (v2). Sequencing was carried out with 150&#x2009;bp paired-end reads on the Illumina HiSeq 4000. Reads alignments to the GRCh37/UCSC hg19 build were achieved using BWA (BWA-MEM v0.7.13). Variants were called using GATK (v3.7 (reference: <ext-link ext-link-type="uri" xlink:href="http://www.broadinstitute.org/gatk/">http://www.broadinstitute.org/gatk/</ext-link>). Annotated Variants were filtered and prioritized using the Bench lab NGS v5.0.2 platform (Agilent technologies). The full exome analysis revealed the compound heterozygous variants in <italic>UGDH</italic>. The family was linked to this cohort via GeneMatcher.</p>
        <p id="Par27"><italic>Family 13</italic>: The exonic regions and flanking splice junctions of the genome were captured using proprietary GeneDx tools. Sequencing was performed on an Illumina system with 100&#x2009;bp or greater paired-end reads. Reads were aligned to the human genome build GRCh37/UCSC hg19. A custom-developed analysis tool (Xome Analyzer) was used to call sequence variants. Sanger sequencing was used to confirm all potentially pathogenic variants identified in available family members. Additional variants not included in this report are available upon request.</p>
        <p id="Par28"><italic>Family 14</italic>: The patient F14-II:1 was enrolled in the ongoing &#x201C;Undiagnosed Patients Program&#x201D; at the Ospedale Pediatrico Bambino Ges&#xF9;, Rome. Targeted enrichment (SureSelect All Exon V.4, Agilent) used genomic DNA extracted from circulating leukocytes for the affected subject and both parents, and parallel sequencing was performed using an Illumina HiSeq2000 platform, obtaining about 70 million reads. The data analysis was performed using an in-house implemented pipeline, which mainly take advantage of the Genome Analysis Toolkit (GATK V.3.7)<sup><xref ref-type="bibr" rid="CR47">47</xref></sup> framework, as previously reported<sup><xref ref-type="bibr" rid="CR48">48</xref>,<xref ref-type="bibr" rid="CR49">49</xref></sup>). The functional annotation of variants was achieved using SnpEff and dbNSFP (V.3.0)<sup><xref ref-type="bibr" rid="CR50">50</xref>&#x2013;<xref ref-type="bibr" rid="CR52">52</xref></sup>. The functional impact of variants was analyzed by Combined Annotation Dependent Depletion (CADD) V.1.3, M-CAP V.1.0, and InterVar V.0.1.6 algorithms<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR53">53</xref>,<xref ref-type="bibr" rid="CR54">54</xref></sup>. Two compound heterozygous private missense variants in the <italic>UGDH</italic> gene, c.347T&#x2009;&gt;&#x2009;C and c.1328G&#x2009;&gt;&#x2009;A, were interpreted as the only candidate genetic etiology.</p>
        <p id="Par29"><italic>Family 15</italic>: genomic DNA from of the proband and parents were enriched for exonic sequences with the SureSelect Human All Exon 50&#x2009;Mb V5 Kit (Agilent Technologies, Santa Clara, California, USA). The HiSeq2500 (Illumina, San Diego, California, USA) was used to generate 125-bp paired-end runs of sequences. Reads were aligned and variant called with DNAnexus (Palo Alto, California, USA) using the reference human genome assembly hg19 (GRCh37). A mean coverage of 104x was achieved for the proband. Data analysis was preformed using an in-house bioinformatics pipeline. The compound heterozygous <italic>UGDH</italic> variants were selected to be the most promising candidates and were thus submitted to GeneMatcher.</p>
      </sec>
      <sec id="Sec10">
        <title>Brain magnetic resonance imaging</title>
        <p id="Par30">Magnetic resonance images (MRI) have been recorded on 1.5 or 3 Tesla scanners at the different clinical sites. Sagittal, transversal, and coronal images of the brain have been acquired with standard sequences, including T1, T2, and Flair images.</p>
      </sec>
      <sec id="Sec11">
        <title>Cell culture</title>
        <p id="Par31">Primary dermal fibroblast cultures were established from skin biopsies obtained from individuals F3-II:1, F4-II:1, F5-I:1, and F5-II:1 according to standard procedures<sup><xref ref-type="bibr" rid="CR55">55</xref></sup>. In brief, primary fibroblasts were derived from biopsy samples and cultured in Dulbecco's modified Eagle medium (DMEM; HyClone, SH30243.01) supplemented with 10% fetal bovine serum (Biological Industries) and 2&#x2009;mM <sc>l</sc>-glutamine (Biological Industries). Written informed consent of healthy probands and parents of UGDH patients were received prior to biopsy according to the ethical approvals of the local Institutional Review Boards (IRB).</p>
      </sec>
      <sec id="Sec12">
        <title>Reverse transcription (RT-PCR) and quantitative PCR</title>
        <p id="Par32">Total RNAs were extracted using the RNeasy Mini Kit (Qiagen). RNA (1&#x2009;&#xB5;g) was reverse transcribed using the Iscript&#x2122; complementary DNA (cDNA) Synthesis Kit (Bio-Rad). Quantitative real-time PCRs were performed using Power SYBR green master mix (Applied Biosystems) on the 7900HT Fast real-time PCR system (Applied Biosystems). qPCR primer sequences are as follows: <italic>UGDH</italic> (between exons 6 and 7) 5&#x2032;CTTGCCCAGAGAATAAGCAG3&#x2032; and 5&#x2032;CAAATTCAGAACATCCTTTTGGA3&#x2032;; <italic>&#x3B2;-ACTIN</italic> 5&#x2032;ATGTTTGAGACCTTCACACC3&#x2032; and 5&#x2032;AGGTAGTCAGTCAGGTCCCGGCC3&#x2032;; <italic>GAPDH</italic> 5&#x2032;TGAACCACCAACTGCTTAGC3&#x2032; and 5&#x2032;GGCATGGACTGTGGTCATGAG3&#x2032;.</p>
      </sec>
      <sec id="Sec13">
        <title>Protein isolation and analysis</title>
        <p id="Par33">Cells were lysed using ice-cold RIPA buffer (250&#x2009;mM Tris, pH: 7.5; 150&#x2009;mM NaCl; 1% NP-40; 0.5% Na deoxycholate; protease inhibitors P2714 [Sigma-Aldrich, USA]). The total protein concentration of cell lysates was determined using the BCA Protein assay Kit (Thermo Fisher Scientific, USA). Sixty micrograms of total proteins were reduced in Laemeli loading buffer, denatured at 95&#x2009;&#xB0;C for 10&#x2009;min, separated by 4&#x2013;20% sodium dodecyl sulfate&#x2013;polyacrylamide gel electrophoresis (Invitrogen, Germany) electrophoresis and transferred onto Immun-Blot&#xAE; Low Fluorescence PVDF Membranes (BIORAD). Protein detection was performed using anti-UGDH (1:500, Sigma-Aldrich, USA, HPA036657) and anti-GAPDH (1:2000, Santa Cruz Biotechnology Inc., USA, SC 47724) antibodies. Secondary antibodies conjugated to peroxidase (1:4000, Santa Cruz Biotechnology Inc., USA) were used and blots were developed using an enhanced chemiluminescence system, Pierce&#x2122; ECL Plus (Thermo Scientific), followed by detection on autoradiographic films.</p>
      </sec>
      <sec id="Sec14">
        <title>HA quantification</title>
        <p id="Par34">HA content was compared in the culture-conditioned media from fibroblasts expressing WT or mutant UGDH using a competitive binding assay as previously described<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. Fibroblasts were grown in 10&#x2009;cm plates, 1&#x2009;mL of conditioned media was aspirated from technical replicates, and cells were counted. HA concentration was interpolated from a standard curve, normalized to cell number, and plotted as mean&#x2009;&#xB1;&#x2009;SD. Statistical significance was assessed by Student&#x2019;s <italic>t</italic>-test with at least three technical triplicates.</p>
      </sec>
      <sec id="Sec15">
        <title>Specific activity measurement of UGDH</title>
        <p id="Par35">Fibroblasts expressing WT or mutant UGDH were assayed for UGDH-specific activity essentially as previously described<sup><xref ref-type="bibr" rid="CR56">56</xref></sup>. Fibroblasts were cultured in 15&#x2009;cm plates, washed three times with cold 1x PBS, and centrifuged at 1500&#x2009;rpm for 5&#x2009;min. Cells were resuspended in twice the pellet volume of Lysis Buffer (50&#x2009;mM Tris-HCl pH 7.4, 150&#x2009;mM NaCl, 1&#x2009;mM EDTA, and protease inhibitor cocktail). Samples were transferred to tubes with an equal volume of acid washed glass beads (Sigma) and lysed in the Bullet Blender 24 (Next Advance) at speed 8 for 3&#x2009;min. The resulting supernatant was centrifuged at 13,000&#x2009;rpm for 15&#x2009;min to obtain final lysates. Enzymatic activity of the lysates (50&#x2009;&#xB5;g) was assayed with 1&#x2009;mM UDP-glucose and 1&#x2009;mM NAD<sup>+</sup> in the presence or absence of 1&#x2009;mM UDP-xylose, a UGDH-specific inhibitor, and monitored for changes in NADH, A<sub>340</sub>. Reaction rates for samples containing UDP-Xyl were subtracted from samples without UDP-Xyl to obtain UGDH-specific activity reported as [NADH] in nmol&#x2009;min<sup>&#x2212;1</sup>&#x2009;mg<sup>&#x2212;1</sup> lysate as described above. Each fibroblast cell line analyzed contained three or more technical replicates for reactions with and without UDP-Xyl plotted as mean&#x2009;&#xB1;&#x2009;SD. Statistical significance was assessed by one-way ANOVA (Prism).</p>
      </sec>
      <sec id="Sec16">
        <title>Generation and purification of <italic>UGDH</italic> point mutants</title>
        <p id="Par36">Point mutants of human UGDH were generated from the codon optimized <italic>E. coli</italic> expression construct, WT-UGDH pET28a, using polymerase chain reaction mutagenesis with appropriate primers as previously described<sup><xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR57">57</xref></sup>. Sequences were verified by Eurofins MWG Operon (Huntsville, AL). The UGDH mutant constructs were expressed in <italic>E. coli</italic> strain BL21(DE3) grown in 2xYT medium containing 50&#x2009;mg&#x2009;L<sup>&#x2212;1</sup> kanamycin at 37&#x2009;&#xB0;C. At an OD<sub>600</sub> of 0.6-0.8, protein expression was induced with the addition of IPTG at a final concentration of 0.5&#x2009;mM, and cultures were incubated at 18&#x2009;&#xB0;C overnight. Cells were harvested by centrifugation and lysed by sonication. All UGDH point mutants were expressed in the soluble fraction, and enzymes were purified by affinity chromatography using a HisTrap FF column (GE Healthcare) according to the manufacturer&#x2019;s protocol. The average protein yields were:&#x2009;~20&#x2009;mg&#x2009;L<sup>&#x2212;1</sup> for UGDH WT and T325D,&#x2009;~1.5&#x2009;mg&#x2009;L<sup>&#x2212;1</sup> for UGDH A82T, and&#x2009;~6&#x2009;mg/L for UGDH A44V. Purified protein was dialyzed against 20&#x2009;mM Tris-HCl pH 7.4 containing 1&#x2009;mM dithiothreitol (DTT), concentrated, flash frozen in liquid nitrogen, and stored at &#x2013;80&#x2009;&#xB0;C.</p>
      </sec>
      <sec id="Sec17">
        <title>Analytical gel filtration</title>
        <p id="Par37">Purified recombinant UGDH WT and all point mutants were analyzed by size exclusion chromatography as previously described<sup><xref ref-type="bibr" rid="CR57">57</xref></sup>. All samples were centrifuged prior to loading. Each apoprotein sample was injected into a 250&#x2009;&#xB5;L loop and separated by FPLC in 1x PBS containing 1&#x2009;mM DTT at a flow rate of 0.5&#x2009;mL&#x2009;min<sup>&#x2212;1</sup> on a Superdex 300 10/200 GL gel filtration column (GE Healthcare). Elution was monitored by A<sub>280</sub> and plotted to compare alterations in oligomeric state.</p>
      </sec>
      <sec id="Sec18">
        <title>Trypsin susceptibility assay</title>
        <p id="Par38">Purified recombinant WT-UGDH and all point mutants were assessed by limited trypsin proteolysis as previously described<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. UGDH WT, A44V (10&#x2009;&#xB5;g), and A82T (14.2&#x2009;&#xB5;g) were digested with 10&#x2009;ng trypsin in 1x PBS pH 7.4 for 2.5&#x2009;h at room temperature in the absence or presence of 1&#x2009;mM UDP-glucose, 1&#x2009;mM UDP-glucuronate, 5&#x2009;mM NAD<sup>+</sup>, 5&#x2009;mM NADH, or combinations that yielded abortive and productive ternary complexes. Samples were analyzed by western blot probed for UGDH as previously described<sup><xref ref-type="bibr" rid="CR58">58</xref></sup>.</p>
      </sec>
      <sec id="Sec19">
        <title>Thermal stability measurement</title>
        <p id="Par39">Recombinant UGDH WT and A44V protein were assessed for thermal stability as previously described<sup><xref ref-type="bibr" rid="CR19">19</xref></sup> with minor alterations. All samples of UGDH WT and A44V (~15&#x2009;&#xB5;g) were incubated in 1x PBS and Sypro Orange dye (Invitrogen; 1:500 dilution) in the absence or presence of 1&#x2009;mM UDP-glucose, 1&#x2009;mM UDP-glucuronate, 5&#x2009;mM NAD<sup>+</sup>, 5&#x2009;mM NADH, or in combinations that yielded abortive and productive ternary complexes. Samples were handled at room temperature and transferred to an iCycler MyiQ thermocycler (Bio-Rad) for incremental thermal denaturation. <italic>T</italic><sub>m</sub> was plotted as the mean&#x2009;&#xB1;&#x2009;SD for seven replicates. Statistical significance was assessed by two-way ANOVA (Prism).</p>
      </sec>
      <sec id="Sec20">
        <title>Saturating enzymatic activity and kinetic characterization</title>
        <p id="Par40">Enzyme activity of recombinant UGDH WT and all point mutants was characterized as described previously<sup><xref ref-type="bibr" rid="CR57">57</xref></sup> with minor alterations. Enzymatic activity was calculated by NADH turnover using the NADH extinction coefficient of 6220&#x2009;M<sup>&#x2212;1</sup>&#x2009;cm<sup>&#x2212;1</sup>. UGDH A82T activity was converted to [NADH] in nmol&#x2009;min<sup>&#x2212;1</sup>&#x2009;mg<sup>&#x2212;1</sup> UGDH and subsequently normalized to the fractional purity of UGDH in the sample preparation. Samples were run in triplicate and statistical significance was determined using Student&#x2019;s <italic>t</italic>-test. Michaelis rate constants, <italic>K</italic><sub>m</sub> and <italic>V</italic><sub>max</sub>, were determined for UGDH WT and A44V as previously described using a 96-well plate assay to measure the change in NADH (A<sub>340</sub>) with respect to both the substrate, UDP-glucose, and cofactor, NAD<sup>+</sup>.</p>
      </sec>
      <sec id="Sec21">
        <title>iPSCs reprogramming</title>
        <p id="Par41">WT, WT/A82T, and A82T/A82T fibroblasts were reprogrammed using the CytoTune&#x2122;-iPS 2.0 Sendai Reprogramming Kit (Thermo Fisher Scientific, A16517) in accordance with the manufacturer&#x2019;s instructions. Briefly, fibroblasts were transduced and plated after 7 days onto Matrigel Basement Membrane Matrix (Corning, 354234) in mTeSR1 medium (STEMCELL Technologies, 85850). iPSC colonies were picked between days 17&#x2013;28 and maintained in Matrigel Basement Membrane Matrix and mTeSR1 for expansion. R393W/A410S, R65*/Y367C, Y14C/S72P fibroblasts were reprogrammed using the ReproRNA&#x2122;-OKSGM kit (Stemcell Technologies, 05930) in accordance with the manufacturer&#x2019;s instructions. Briefly, fibroblasts were plated onto Matrigel Basement Membrane Matrix (Corning, 354234) and transfected with ReproRNA&#x2122;-OKSGM cocktail. Puromycin selection was carried out 1 day after transfection. iPSC colonies were picked between 20 and 28 days after transfection and maintained in Matrigel Basement Membrane Matrix and mTeSR1 for expansion. Between 1 and 3 clones per genotype were maintained for further experiments.</p>
      </sec>
      <sec id="Sec22">
        <title>Neuronal and cerebral organoid differentiation</title>
        <p id="Par42">Neuronal and cerebral organoid differentiation was performed as previously described<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. Briefly, on day 0 of organoid culture, iPSCs were dissociated by accutase (STEMCELL Technologies, 07920) treatment to generate single cells. In total, 9000 cells were then plated per well of an ultra-low-binding 96-well plate (Corning) in MEDI medium [Knockout SR 20% (Thermo Fisher scientific, 10828-028), <sc>l</sc>-glutamine 2&#x2009;mM (Thermo Fisher scientific, 200&#x2009;mM, 25030-081), Non-essential amino-acid (NEAA) 1&#x2009;&#xD7;&#x2009;(Thermo Fisher scientific, 100&#xD7;&#x2009;, 11140-050), sodium pyruvate 1&#xD7;&#x2009;(Thermo Fisher scientific, 100&#x2009;mM, 11360-070), and &#x3B2;-mercaptoethanol 1/1000 in neurobasal medium (Thermo Fisher scientific, A2477-501)] complemented with 10&#x2009;&#xB5;M Rho-associated protein kinase (ROCK) inhibitor (STEMCELL technology, Y-27632) and 0.05% polyvinyl alcohol. Embryoid bodies were fed with this medium every other day for 6 days. Then, MEDI medium was replaced with NIM-I medium [N2 1&#xD7;&#x2009;(Thermo Fisher scientific, 100&#xD7;&#x2009;, 17502-048), <sc>l</sc>-glutamine 2&#x2009;mM, NEAA 1&#xD7;&#x2009;, and heparin 1&#x2009;&#xB5;g&#x2009;mL<sup>&#x2212;1</sup> (Sigma-Aldrich, H3149) in neurobasal medium] every other day for 6 additional days for the neuroepithelial tissues induction. On day 11, tissues exhibiting neural ectoderm were transferred to droplets of cold Matrigel (BD Biosciences) on a sheet of Parafilm with dimples in a low-adhesion 6-well plate (Corning). These droplets were allowed to gel at 37&#x2009;&#xB0;C and were subsequently removed from the Parafilm and grown in differentiation medium Dif-M [N2 0.5&#x2009;&#xD7;&#x2009;, B27 without vitamin A 1&#xD7;&#x2009;(Thermo Fisher scientific, 50&#x2009;&#xD7;&#x2009;, 12587-010), <sc>l</sc>-glutamine 2&#x2009;mM, NEAA 1&#xD7;&#x2009;, and &#x3B2;-mercaptoethanol 1/1000 in neurobasal medium] for 4 days. On day 15, the medium was replaced by Dif-M II medium [N2 0.5&#xD7;&#x2009;, B27 1&#xD7;&#x2009;(Thermo Fisher scientific, 50&#xD7;&#x2009;, 17504-001), <sc>l</sc>-glutamine 2&#x2009;mM, NEAA 1&#xD7;&#x2009;, and &#x3B2;-mercaptoethanol 1/1000 in neurobasal medium], and the plates are placed on a horizontal shaker rotating at 85&#x2009;rpm. Cerebral organoids were grown up to 10 weeks with 75% of the medium changed weekly.</p>
      </sec>
      <sec id="Sec23">
        <title>Histology and immunofluorescence of organoids</title>
        <p id="Par43">Cerebral organoids were fixed in 4% paraformaldehyde (PFA) overnight at 4&#x2009;&#xB0;C, then washed in PBS for 10&#x2009;min and dehydrated by incubations in Ethanol (70%, 95% then 100%) for 1&#x2009;h at 4&#x2009;&#xB0;C followed by two times 1&#x2009;h incubation with Xylene 100% at room temperature. The cerebral organoids were then embedded in Paraplast Plus (Leica, 39602004) and sectioned at 30&#x2009;&#xB5;m. Tissue sections were stained with Haematoxylin and Eosin (H&amp;E) or used for immunostaining. For immunofluorescence, antigen retrieval was performed by using the Antigen Retriever buffer (Citrate Buffer pH 6.0, Sigma, C 9999, 10&#xD7;&#x2009;). Sections were then blocked and permeabilized in blocking buffer (0.5% Triton X-100 and 1% BSA in PBS) for 20&#x2009;min. Sections were then incubated with primary antibodies in blocking buffer at the following dilutions: SOX2 (mouse, R&amp;D systems, MAB2018, 1:200), TUJ1 (mouse, Biolegend MMS-435P, 1:3000), GFAP (Rabbit, Dako Z0334, 1/2500), PCNA (Rabbit, abcam ab18197, 1&#x2009;&#xB5;g&#x2009;mL<sup>&#x2212;1</sup>). For visualization, an antibody anti-mouse immunoglobulin G (anti&#x2013;mouse IgG) Alexa Fluor 594 conjugate (Invitrogen, Molecular Probes) and an anti-rabbit IgG Alexa Fluor 488 conjugate (Invitrogen, Molecular Probes) was applied. DNA was stained by DAPI (1/500) and sections were mounted in ProLong Diamond Antifade mountant (Thermo Fisher Scientific, P36965). Images were collected by using an Olympus FV3000 RS with a 20x objective.</p>
      </sec>
      <sec id="Sec24">
        <title>RT and RT-qPCR</title>
        <p id="Par44">Total RNA of individual cerebral organoids was extracted using the RNeasy Mini Kit (Qiagen, 74104). Total RNA (0.5&#x2009;&#xB5;g) was reverse transcribed using the Iscript&#x2122; cDNA Synthesis Kit (Bio-Rad, 1708891). Real-time quantitative PCRs were performed using the Power SYBR green master mix (Applied Biosystems, 4309155) on the 7900HT Fast real-time PCR system (Applied Biosystems). qPCR primers were as previously described:<sup><xref ref-type="bibr" rid="CR59">59</xref></sup>
<italic>PAX6</italic> 5&#x2032;CCGTGTGCCTCAACCGTA3&#x2032; and 5&#x2032;CACGGTTTACTGGGTCTGG3&#x2032;; <italic>TBR2</italic> 5&#x2032;AAATGGGTGACCTGTGGCAAAGC3&#x2032; and 5&#x2032;CTCCTGTCTCATCCAGTGGGAA3&#x2032;; <italic>TUJ1</italic> 5&#x2032;TCAGCGTCTACTACAACGAGGC3&#x2032; and 5&#x2032;GCCTGAAGAGATGTCCAAAGGC3&#x2032;.</p>
      </sec>
      <sec id="Sec25">
        <title>Neural induction</title>
        <p id="Par45">Neural induction was carried out by dual SMAD inhibition<sup><xref ref-type="bibr" rid="CR60">60</xref></sup>. iPSC were first dissociated into single cells and seeded in low attachment 96-well u-bottom plate at a density of 10,000 cells/well in Neural Induction Medium [DMEM/F12 (Thermo Fisher Scientific, 10565-018) supplemented with B27 (Thermo Fisher Scientific, 17504044), N2 (Thermo Fisher Scientific, 17505048), 0.2&#x2009;mM NEAA (Thermo Fisher Scientific, 11140-050), 100&#x2009;nM LDN 193189 (STEMCELL Technologies, 72148), 10&#x2009;&#xB5;M SB431542 (STEMCELL Technologies, 72234) and 10&#x2009;&#xB5;M Y-27632 (STEMCELL Technologies, 72304)]. After 6 days, cells were attached onto matrigel coated-plate in Neural Expansion Medium [DMEM/F12 (Thermo Fisher Scientific, 10565-018) supplemented with B27 (Thermo Fisher Scientific, 17504044), N2 (Thermo Fisher Scientific, 17505048), 0.2&#x2009;mM NEAA (Thermo Fisher Scientific, 11140-050) and 20&#x2009;ng&#x2009;mL<sup>&#x2212;1</sup> &#x3B2;FGF (Stemgent, 03-0002)]. After 3&#x2013;6 days, rosette structures were manually cut out and expanded as suspension culture in neural expansion medium.</p>
      </sec>
      <sec id="Sec26">
        <title>Neuronal differentiation</title>
        <p id="Par46">iPSCs-derived Neuro-Precursor Cells (NPCs) were differentiated into neurons for 21 days using a previously published protocol<sup><xref ref-type="bibr" rid="CR61">61</xref></sup> Briefly, NPCs were plated at a density of 50,000&#x2009;cells&#x2009;cm<sup>&#x2212;2</sup> in a poly-<sc>l</sc>-ornithine and laminin-coated plates, cultured in N2B27 medium supplemented BDNF (20&#x2009;ng&#x2009;mL<sup>&#x2212;1</sup>), GDNF (20&#x2009;ng&#x2009;mL<sup>&#x2212;1</sup>), cAMP (N6,2&#x2032;-O-dibutyryladenosine 3&#x2032;,5&#x2032;-cyclic monophosphate; Sigma; 0.3&#x2009;mM) and ascorbic acid (0.2&#x2009;mM).</p>
      </sec>
      <sec id="Sec27">
        <title>Multi-electrode Array (MEA) recordings</title>
        <p id="Par47">Neurons on day 21 were dissociated and replated on 0.1 polyethylenimine (Sigma)-coated 48-well MEA plates (Axion Biosystems) in BrainPhys media supplemented with BDNF, GDNF, cAMP, and ascorbic acid as previously described<sup><xref ref-type="bibr" rid="CR62">62</xref></sup>. Spontaneous neuronal activity was observed and recorded at 37<sup>o</sup>&#x2009;C for 5&#x2009;min every 2&#x2013;3 days using the Maestro MEA System (Axion Biosystem).</p>
      </sec>
      <sec id="Sec28">
        <title>Zebrafish strains and maintenance</title>
        <p id="Par48">All zebrafish husbandry procedures were performed in compliance with the Singapore National Advisory Committee on Laboratory Animal Research Guidelines from the Institutional Animal Care and Use Committee (IACUC, IACUC number 161172). The <italic>jek ugdh</italic><sup><italic>m151</italic></sup> mutant line<sup><xref ref-type="bibr" rid="CR63">63</xref></sup> was used for this study and was maintained in the AB background. All embryos were raised in egg water (5&#x2009;mM NaCl, 0.17&#x2009;mM KCl, 0.33&#x2009;mM CaCl<sub><bold>2</bold></sub>, 0.33&#x2009;mM MgSO<sub><bold>4</bold></sub>).</p>
      </sec>
      <sec id="Sec29">
        <title>Genomic DNA extraction</title>
        <p id="Par49">Genomic DNA from larvae used for the locomotion assay was extracted by larval fin clipping as previously described<sup><xref ref-type="bibr" rid="CR64">64</xref></sup>. Briefly, microscopic caudal fin slices of 3-dpf larvae were sectioned under a stereomicroscope. The fins were then digested with proteinase K (Invitrogen, 25530049) overnight at 65&#x2009;&#xB0;C, and the supernatant was used as a source of genomic DNA for genotyping. In 7-dpf larvae, heads were used for <italic>c-fos</italic> qPCR analysis, while the rest of the bodies was used for genotyping.</p>
      </sec>
      <sec id="Sec30">
        <title>Genotyping of zebrafish</title>
        <p id="Par50">Genotyping was performed via nested PCR to amplify the exon 7 of <italic>ugdh</italic>, and restriction fragment length polymorphism as described previously<sup><xref ref-type="bibr" rid="CR63">63</xref></sup>. The first PCR was performed with the following primers, 5&#x2032;-TGTATGTGCAGGTGATTGACA-3&#x2032; and 5&#x2032;-TGTAGGTCACAGGTTTTTGACA-3&#x2032;. PCR products were cleaned-up by Exonuclease I (New England Biolabs, M0293L) and FastAP Thermosensitive Alkaline Phosphatase (Thermo Fisher, EF0651) treatment, and were then used as templates for a second PCR with the following primers: 5&#x2032;-GACATGAATGAATATCAGAGAAAGAG-3&#x2032; and 5&#x2032;-AGGAGAAACCCAACAACGC-3&#x2032;. These PCR products were digested with the <italic>MluI</italic> enzyme (New England Biolabs, R3198L) that only cuts when the mutation is present.</p>
      </sec>
      <sec id="Sec31">
        <title><italic>c-fos</italic> qPCR experiments</title>
        <p id="Par51">7-dpf larvae were first incubated with increasing concentrations (up to 15&#x2009;mM) of PTZ (Sigma, P6500) for 45&#x2009;min and were then decapitated. The bodies were used for genotyping and 20 larvae heads of the same genotype were pooled together for total RNA extraction using the RNeasy Mini Kit (Qiagen, 74104). Total RNA (0.5&#x2009;&#xB5;g) was reverse transcribed using the Iscript&#x2122; cDNA Synthesis Kit (Bio-Rad, 1708891). Real-time quantitative PCRs were performed using the Power SYBR green master mix (Applied Biosystems, 4309155) on the 7900HT Fast real-time PCR system (Applied Biosystems). qPCR primers were as follows: <italic>c-fos</italic><sup><xref ref-type="bibr" rid="CR23">23</xref></sup> 5&#x2032;-AACTGTCACGGCGATCTCTT-3&#x2032; and 5&#x2032;-GCAGGCATGTATGGTTCAGA-3&#x2032;; <italic>gapdh</italic> 5&#x2032;-GTGGAGTCTACTGGTGTCTT-3&#x2032; and 5&#x2032;-GTGCAGGAGGCATTGCTTAC-3&#x2032;.</p>
      </sec>
      <sec id="Sec32">
        <title>Twenty-four-well locomotion and convulsion test assay</title>
        <p id="Par52">A Basler Ace (acA1300-200um; 1280&#x2009;&#xD7;&#x2009;1024) camera was used to acquire videos of larval zebrafish at 50&#x2009;fps. A custom hardware setup was designed to acquire full frame videos of 24-well flat bottom plates using a 25&#x2009;mm lens attachment to the camera placed 65&#x2009;cm above the plate. The 24-well plates were backlit using a white light LED lightbox that delivered uniform lighting across the entire field. 7-dpf larval fish were placed individually in each well in 500&#x2009;&#xB5;l of egg water and acclimated to the setup for 10&#x2009;min. Then, 500&#x2009;&#xB5;l of either egg water (negative control) or PTZ 30&#x2009;mM (15&#x2009;mM final concentration, Sigma, P6500) was added to the well. Three videos of 2&#x2009;min each were acquired for a duration of 10&#x2009;min for each condition tested. Fish locomotion was tracked online during video recording on a custom written software in LabView (<ext-link ext-link-type="uri" xlink:href="http://www.critta.org">www.critta.org</ext-link>). Analysis of locomotion was automated and performed blind offline after each experiment using custom written Python scripts (available on Github: <ext-link ext-link-type="uri" xlink:href="https://github.com/mechunderlyingbehavior/24-Well-Larval-Locomotion.git">https://github.com/mechunderlyingbehavior/24-Well-Larval-Locomotion.git</ext-link>). In this assay, low and high speed were defined as average speeds of 0 to 8&#x2009;mm/s and&#x2009;&gt;8&#x2009;mm&#x2009;s<sup>&#x2212;1</sup>, respectively, based on a recent publication measuring convulsive-induced speed changes in zebrafish larvae<sup><xref ref-type="bibr" rid="CR65">65</xref></sup>.</p>
      </sec>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Supplementary information</title>
      <sec id="Sec33">
        <p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41467_2020_14360_MOESM1_ESM.pdf"><caption><p>Supplementary Information</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="41467_2020_14360_MOESM2_ESM.xlsx"><caption><p>Supplementary Data 1</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="41467_2020_14360_MOESM3_ESM.pdf"><caption><p>Description of Additional Supplementary Files</p></caption></media></supplementary-material>
</p>
      </sec>
    </sec>
  </body>
  <back>
    <app-group>
      <app id="App1">
        <sec id="Sec34">
          <title>Source data</title>
          <p id="Par55">
<media position="anchor" xlink:href="41467_2020_14360_MOESM4_ESM.zip" id="MOESM4"><caption><p>Source Data</p></caption></media>
</p>
        </sec>
      </app>
    </app-group>
    <fn-group>
      <fn>
        <p><bold>Peer review information</bold>
<italic>Nature Communications</italic> thanks the anonymous reviewers for their contribution to the peer review of this work.</p>
      </fn>
      <fn>
        <p><bold>Publisher&#x2019;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
      </fn>
      <fn>
        <p>These authors contributed equally: Holger Hengel, C&#xE9;lia Bosso-Lef&#xE8;vre</p>
      </fn>
    </fn-group>
    <sec>
      <title>Supplementary information</title>
      <p><bold>Supplementary information</bold> is available for this paper at 10.1038/s41467-020-14360-7.</p>
    </sec>
    <ack>
      <title>Acknowledgements</title>
      <p>We are grateful to the families of affected individuals whose cooperation made this study possible. We would like to thank Dr. Mary-Claire King from the University of Washington (Seattle, USA) and Dr. Ephrat Levy-Lahad (Medical Genetics Institute Shaare Zedek Medical Center, Israel) who independently investigated Family 1 and completed the segregation of the <italic>UGDH</italic> mutations in available family members. This study has been supported by the German Research Foundation (DFG, grant SCHO754/5-2 to L.S. and H.M.M.), by the European Union through funding for the NEUROMICS network (F5-2012-305121 to L.S.), by A Strategic Positioning Fund on Genetic Orphan Diseases (GODAFIT) and an Industry Alignment Fund on Singapore Childhood Undiagnosed Diseases Program (SUREKids) from the Biomedical Research Council, A*STAR, Singapore. T.M.P. was supported by the Diana and Steve Marienhoff Fashion Industries Guild Endowed Fellowship in Pediatric Neuromuscular Diseases. M.T. was supported by the Fondazione Bambino Ges&#xF9; (Vite Coraggiose) whose study was in the frame of the ongoing &#x201C;Undiagnosed Patients Program&#x201D;, Ospedale Pediatrico Bambino Ges&#xF9;, Rome. B.C. is supported by operating grants from the Canadian Institutes of Health Research and the Natural Sciences and Engineering Research Council of Canada. S.W. is supported by the Eurocores program EuroEPINOMICS, the Fund for Scientific Research Flanders (FWO), the International Coordination Action (ICA) grant G0E8614N, and the University of Antwerp (research fund). H.S. is a Ph.D fellow of the Fund for Scientific Research Flanders (1125416&#x2009;N). D.J.L. received financial support obtained from the Netherlands Organization for Scientific Research (ZONMW VIDI grant 91713359 to D.J.L.). S.S.J. is supported by National Medical Research Council, Singapore (NMRC/CISSP/0003/2016). B.R. is a fellow of the Branco Weiss Foundation, an A*STAR Investigator, a Young EMBO Investigator, a Senior NRF and AAA fellow. K.H.U was supported by the FRAXA Foundation. Furthermore, we would like to thank the EuroEPINOMICS-RES NLES Working Group for their support by screening their database and matching Family 3.&#xA0;T.B. is supported by the Netherlands Organisation for Scientific Research (ZonMW Veni, grant 91617021) and by an NARSAD Young Investigator Grant from the Brain &amp; Behavior Research Foundation.</p>
    </ack>
    <notes notes-type="author-contribution">
      <title>Author contributions</title>
      <p>B.R., C.B.-L., E.S.-R., H.H., L.S. designed the study. B.R., C.B.-L., H.H., L.S. co-wrote the paper. B.R., E.S.-R., H.H., L.S. supervised the study. D.J.L., E.S.-R., J.J.B., M.A.S. contributed to writing the paper. S.S.J. (F5) recognized this disease as a new clinical entity with the F5. H.H. coordinated the clinical data and phenotyping. A.R. analyzed dysmorphic features, and reviewed of all available pictures. I.K.-M. interpreted the MRI data. F.S.A. (F11, F20) and M.M.A. (F23) coordinated the local clinical study. H.V. (F3) and S.W. (F3) designed and supervised local genetic study. A.A. (F11, F20), M.A. (F11, F20), R.H.G. (F13), M.J.M. (F2), H.V. (F3), D.H. (F6), D.A.K. (F7, F8, F16-F19), T.M.P. (F9), W.G.M. (F9), and H.H. made clinical diagnosis. H.M.M. (F1), N.H. (F1), R.K. (F1), W.D. (F1), M.C.W. (F10), M.V.A. (F10), L.H.R. (F11), T.B. (F12), R.H.G. (F13), T.G. (F15), A.A.H.M. (F16-F19), E.A.F. (F16-F19), L.A.J. (F16-F19), S.M.A. (F16-F19), A.A.A. (F16-F19), A.M.T. (F21), M.O.H (F21), H.V. (F3), S.W. (F3),S.D. (F4), S.N. (F4), I.H. (F4, F9), E.T. (F5), J.L. (F5), T.T. (F5), M.A.A.P.W. (F7), R.O. (F8), D.M. (F14) M.D.S. (F23), M.M.A. (F23), and H.M.D. (F24, F25) collected the clinical data. H.V. (F3), S.W. (F3) designed and supervised local genetic study. M.C.W. (F10), M.V.A. (F10), E.W.K. (F13), L.S.R. (F13), M.G.-A. (F2), M.J.M. (F2), and H.M.D. (F24, F25) provided genetic evaluation. A.Y.J.N. (F5), D.A.K(F7, F8, F16-F19) collected DNA samples. H.H. (F1), P.B. (F1), A.B. (F2, F9, F10), A.T. (F2, F9, F10), H.S. (F3), S.W. (F3), S.Ta. (F4), A.Y.J.N. (F5), B.V. (F5), C.B. (F5), S.To. (F5), B.K. (F6), D.A.K. (F7, F8, F16-F19), R.P. (F7, F8, F16-F19), T.M.P. (F9), S.B. (F14),, H.M.-S. (F15), S.M. (F22), and R.S. performed WES sequencing and analyses. H.H. (F1), S.G. (F1), F.S.A. (F11, F20), C.B. (F5), M.T. (F14), and S.M. (F22) identified the gene. B.R., L.S. did matchmaking with GeneMatcher, and R.S. with Genesis. M.A.S. designed biochemical and cell culture studies. J.J.B. designed structural and biochemical studies. D.J.L. provided glycosylation expertize. C.B.-L., D.J.L., G.G., S.B.P. performed biochemical studies. E.L. (F6), C.B.-L., G.G. performed cell culture experiments. T.T., G.N., and M.Y.E. performed reprogramming experiments. K.H.U. and M.A.P. designed and performed neuronal cell culture and multi-electrode array. C.B.-L. performed cerebral organoids differentiation, staining and analysis. B.C. shared the <italic>jekyll m151</italic> zebrafish line. A.C.-C., A.S.M., J.C.S. designed hardware and software, and A.S.M., H.L. designed automated scripts for zebrafish behavior studies. B.C., M.Y. performed functional genetic studies, and C.B.-L. performed behavior and PTZ experiments in zebrafish.</p>
    </notes>
    <notes notes-type="data-availability">
      <title>Data availability</title>
      <p>The data that support the findings of this study are available within the paper and its supplementary information files. All identified variants have been deposited in the ClinVar database (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/clinvar/">https://www.ncbi.nlm.nih.gov/clinvar/</ext-link>) under the name &#x201C;UGDH001&#x201D;. Whole dataset from Family F3 was already published<sup><xref ref-type="bibr" rid="CR66">66</xref></sup> and deposited in the European Genome-phenome Archive, accession numbers EGAS00001000190, EGAS00001000386, and EGAS00001000048. Whole datasets from Families F5 and F15 are available upon request from the corresponding authors. Consent restrictions preclude deposition of sequencing data of the other families, however, specific information (e.g., secondary variants etc., but not full datasets) can be obtained upon request from the corresponding authors. Lists of primers and antibodies are in Supplementary Tables&#xA0;<xref rid="MOESM1" ref-type="media">4</xref> and <xref rid="MOESM1" ref-type="media">5</xref>, respectively. The source data underlying Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>a&#x2013;f, Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4a, and c</xref>, Suppl. Fig.&#xA0;<xref rid="MOESM1" ref-type="media">3</xref>a&#x2013;d, Suppl. Fig.&#xA0;<xref rid="MOESM1" ref-type="media">4a, b, and d</xref> are provided as a Source Data file 1 (for gels) and 2 (for graphs).</p>
    </notes>
    <notes notes-type="data-availability">
      <title>Code availability</title>
      <p>The custom written Python scripts used to track fish locomotion is available following this link: <ext-link ext-link-type="uri" xlink:href="https://github.com/mechunderlyingbehavior/24-Well-Larval-Locomotion.git">https://github.com/mechunderlyingbehavior/24-Well-Larval-Locomotion.git</ext-link>.</p>
    </notes>
    <notes notes-type="COI-statement">
      <title>Competing interests</title>
      <p id="Par53">The authors declare the following competing interests: P.B. is employed by and receives a salary from Centogene AG (Exome sequencing is among the commercially available tests). S.Ta. is employed by and receive a salary from Ambry Genetics (exome sequencing is a commercially available test). A.B. and A.T. are employees of GeneDx (exome sequencing is a commercially available test). S.S.J. is co-founder of Global Gene Corporation Pte Ltd., however, there are no competing financial interests.&#xA0;The remaining authors declare no competing interests.</p>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Scheffer</surname>
              <given-names>IE</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology</article-title>
          <source>Epilepsia</source>
          <year>2017</year>
          <volume>58</volume>
          <fpage>512</fpage>
          <lpage>521</lpage>
          <pub-id pub-id-type="doi">10.1111/epi.13709</pub-id>
          <pub-id pub-id-type="pmid">28276062</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McTague</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Howell</surname>
              <given-names>KB</given-names>
            </name>
            <name>
              <surname>Cross</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Kurian</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Scheffer</surname>
              <given-names>IE</given-names>
            </name>
          </person-group>
          <article-title>The genetic landscape of the epileptic encephalopathies of infancy and childhood</article-title>
          <source>Lancet Neurol.</source>
          <year>2016</year>
          <volume>15</volume>
          <fpage>304</fpage>
          <lpage>316</lpage>
          <pub-id pub-id-type="doi">10.1016/S1474-4422(15)00250-1</pub-id>
          <pub-id pub-id-type="pmid">26597089</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Freeze</surname>
              <given-names>HH</given-names>
            </name>
            <name>
              <surname>Eklund</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Ng</surname>
              <given-names>BG</given-names>
            </name>
            <name>
              <surname>Patterson</surname>
              <given-names>MC</given-names>
            </name>
          </person-group>
          <article-title>Neurological aspects of human glycosylation disorders</article-title>
          <source>Annu. Rev. Neurosci.</source>
          <year>2015</year>
          <volume>38</volume>
          <fpage>105</fpage>
          <lpage>125</lpage>
          <pub-id pub-id-type="doi">10.1146/annurev-neuro-071714-034019</pub-id>
          <pub-id pub-id-type="pmid">25840006</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Morava</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Vodopiutz</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Lefeber</surname>
              <given-names>D. J.</given-names>
            </name>
            <name>
              <surname>Janecke</surname>
              <given-names>A. R.</given-names>
            </name>
            <name>
              <surname>Schmidt</surname>
              <given-names>W. M.</given-names>
            </name>
            <name>
              <surname>Lechner</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Item</surname>
              <given-names>C. B.</given-names>
            </name>
            <name>
              <surname>Sykut-Cegielska</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Adamowicz</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Wierzba</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Z. H.</given-names>
            </name>
            <name>
              <surname>Mihalek</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Stockler</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Bodamer</surname>
              <given-names>O. A.</given-names>
            </name>
            <name>
              <surname>Lehle</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Wevers</surname>
              <given-names>R. A.</given-names>
            </name>
          </person-group>
          <article-title>Defining the Phenotype in Congenital Disorder of Glycosylation Due to ALG1 Mutations</article-title>
          <source>PEDIATRICS</source>
          <year>2012</year>
          <volume>130</volume>
          <issue>4</issue>
          <fpage>e1034</fpage>
          <lpage>e1039</lpage>
          <pub-id pub-id-type="doi">10.1542/peds.2011-2711</pub-id>
          <pub-id pub-id-type="pmid">22966035</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wu</surname>
              <given-names>X</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Deficiency of UDP-GlcNac:dolichol phosphate N-acetylglucosamine-1 phosphate transferase (DPAGT1) causes a novel congenital disorder of glycosylation type Ij</article-title>
          <source>Hum. Mutat.</source>
          <year>2003</year>
          <volume>22</volume>
          <fpage>144</fpage>
          <lpage>150</lpage>
          <pub-id pub-id-type="doi">10.1002/humu.10239</pub-id>
          <pub-id pub-id-type="pmid">12872255</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Egger</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Chaikuad</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kavanagh</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Oppermann</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Nidetzky</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Structure and mechanism of human UDP-glucose 6-dehydrogenase</article-title>
          <source>J. Biol. Chem.</source>
          <year>2011</year>
          <volume>286</volume>
          <fpage>23877</fpage>
          <lpage>23887</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M111.234682</pub-id>
          <pub-id pub-id-type="pmid">21502315</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Egger</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Structural and kinetic evidence that catalytic reaction of human UPD-glucose 6-dehydrogenase involves covalent thiohemiacetal and thioester enzyme intermediates</article-title>
          <source>J. Biol. Chem.</source>
          <year>2012</year>
          <volume>287</volume>
          <fpage>2119</fpage>
          <lpage>2129</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M111.313015</pub-id>
          <pub-id pub-id-type="pmid">22123821</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pollard</surname>
              <given-names>KS</given-names>
            </name>
            <name>
              <surname>Hubisz</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Rosenbloom</surname>
              <given-names>KR</given-names>
            </name>
            <name>
              <surname>Siepel</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Detection of nonneutral substitution rates on mammalian phylogenies</article-title>
          <source>Genome Res.</source>
          <year>2010</year>
          <volume>20</volume>
          <fpage>110</fpage>
          <lpage>121</lpage>
          <pub-id pub-id-type="doi">10.1101/gr.097857.109</pub-id>
          <pub-id pub-id-type="pmid">19858363</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <mixed-citation publication-type="other">EVS. Exome Variant Server. <italic>NHLBI GO Exome Sequencing Project (ESP)</italic> (EVS, 2014).</mixed-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lek</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Analysis of protein-coding genetic variation in 60,706 humans</article-title>
          <source>Nature</source>
          <year>2016</year>
          <volume>536</volume>
          <fpage>285</fpage>
          <lpage>291</lpage>
          <pub-id pub-id-type="doi">10.1038/nature19057</pub-id>
          <pub-id pub-id-type="pmid">27535533</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kircher</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A general framework for estimating the relative pathogenicity of human genetic variants</article-title>
          <source>Nat. Genet.</source>
          <year>2014</year>
          <volume>46</volume>
          <fpage>310</fpage>
          <lpage>315</lpage>
          <pub-id pub-id-type="doi">10.1038/ng.2892</pub-id>
          <pub-id pub-id-type="pmid">24487276</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gonzalez</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Innovative genomic collaboration using the GENESIS (GEM.app) platform</article-title>
          <source>Hum. Mutat.</source>
          <year>2015</year>
          <volume>36</volume>
          <fpage>950</fpage>
          <lpage>956</lpage>
          <pub-id pub-id-type="doi">10.1002/humu.22836</pub-id>
          <pub-id pub-id-type="pmid">26173844</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sobreira</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Schiettecatte</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Valle</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Hamosh</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>GeneMatcher: a matching tool for connecting investigators with an interest in the same gene</article-title>
          <source>Hum. Mutat.</source>
          <year>2015</year>
          <volume>36</volume>
          <fpage>928</fpage>
          <lpage>930</lpage>
          <pub-id pub-id-type="doi">10.1002/humu.22844</pub-id>
          <pub-id pub-id-type="pmid">26220891</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rajakannan</surname>
              <given-names>Venkatachalam</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>Hui-Sun</given-names>
            </name>
            <name>
              <surname>Chong</surname>
              <given-names>Seon-Ha</given-names>
            </name>
            <name>
              <surname>Ryu</surname>
              <given-names>Han-Bong</given-names>
            </name>
            <name>
              <surname>Bae</surname>
              <given-names>Ji-Young</given-names>
            </name>
            <name>
              <surname>Whang</surname>
              <given-names>Eun-Young</given-names>
            </name>
            <name>
              <surname>Huh</surname>
              <given-names>Jae-Wan</given-names>
            </name>
            <name>
              <surname>Cho</surname>
              <given-names>Sung-Woo</given-names>
            </name>
            <name>
              <surname>Kang</surname>
              <given-names>Lin-Woo</given-names>
            </name>
            <name>
              <surname>Choe</surname>
              <given-names>Han</given-names>
            </name>
            <name>
              <surname>Robinson</surname>
              <given-names>Robert C.</given-names>
            </name>
          </person-group>
          <article-title>Structural Basis of Cooperativity in Human UDP-Glucose Dehydrogenase</article-title>
          <source>PLoS ONE</source>
          <year>2011</year>
          <volume>6</volume>
          <issue>10</issue>
          <fpage>e25226</fpage>
          <pub-id pub-id-type="doi">10.1371/journal.pone.0025226</pub-id>
          <pub-id pub-id-type="pmid">21984906</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sommer</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Barycki</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Simpson</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Characterization of human UDP-glucose dehydrogenase: CYS-276 is required for the second of two successive oxidations</article-title>
          <source>J. Biol. Chem.</source>
          <year>2004</year>
          <volume>279</volume>
          <fpage>23590</fpage>
          <lpage>23596</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M401928200</pub-id>
          <pub-id pub-id-type="pmid">15044486</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Desmet</surname>
              <given-names>FO</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Human splicing finder: an online bioinformatics tool to predict splicing signals</article-title>
          <source>Nucl. Acids Res.</source>
          <year>2009</year>
          <volume>37</volume>
          <fpage>1</fpage>
          <lpage>14</lpage>
          <pub-id pub-id-type="doi">10.1093/nar/gkp215</pub-id>
          <pub-id pub-id-type="pmid">19033363</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pires</surname>
              <given-names>DEV</given-names>
            </name>
            <name>
              <surname>Ascher</surname>
              <given-names>DB</given-names>
            </name>
            <name>
              <surname>Blundell</surname>
              <given-names>TL</given-names>
            </name>
          </person-group>
          <article-title>DUET: a server for predicting effects of mutations on protein stability using an integrated computational approach</article-title>
          <source>Nucl. Acids Res.</source>
          <year>2014</year>
          <volume>42</volume>
          <fpage>314</fpage>
          <lpage>319</lpage>
          <pub-id pub-id-type="doi">10.1093/nar/gku411</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Egger</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Chaikuad</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kavanagh</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Oppermann</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Nidetzky</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>UDP-glucose dehydrogenase: structure and function of a potential drug target</article-title>
          <source>Biochem. Soc. Trans.</source>
          <year>2010</year>
          <volume>38</volume>
          <fpage>1378</fpage>
          <lpage>1385</lpage>
          <pub-id pub-id-type="doi">10.1042/BST0381378</pub-id>
          <pub-id pub-id-type="pmid">20863317</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hyde</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Thelen</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Barycki</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Simpson</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>UDP-glucose dehydrogenase activity and optimal downstream cellular function require dynamic reorganization at the dimer-dimer subunit interfaces</article-title>
          <source>J. Biol. Chem.</source>
          <year>2013</year>
          <volume>288</volume>
          <fpage>35049</fpage>
          <lpage>35057</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M113.519090</pub-id>
          <pub-id pub-id-type="pmid">24145036</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <mixed-citation publication-type="other">Neuhauss, S. C. et al. Mutations affecting craniofacial development in zebrafish. <italic>Development</italic><bold>123</bold>, 357&#x2013;367 (1997).</mixed-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stainier</surname>
              <given-names>DY</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mutations affecting the formation and function of the cardiovascular system in the zebrafish embryo</article-title>
          <source>Development</source>
          <year>1996</year>
          <volume>123</volume>
          <fpage>285</fpage>
          <lpage>292</lpage>
          <pub-id pub-id-type="pmid">9007248</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Driever</surname>
              <given-names>W</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A genetic screen for mutations affecting embryogenesis in zebrafish</article-title>
          <source>Development</source>
          <year>1996</year>
          <volume>123</volume>
          <fpage>37</fpage>
          <lpage>46</lpage>
          <pub-id pub-id-type="pmid">9007227</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baraban</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Castro</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Baier</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Pentylenetetrazole induced changes in zebrafish behavior, neural activity and c-fos expression</article-title>
          <source>Neuroscience</source>
          <year>2005</year>
          <volume>131</volume>
          <fpage>759</fpage>
          <lpage>768</lpage>
          <pub-id pub-id-type="doi">10.1016/j.neuroscience.2004.11.031</pub-id>
          <pub-id pub-id-type="pmid">15730879</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>C-Fos regulates neuronal excitability and survival</article-title>
          <source>Nat. Genet.</source>
          <year>2002</year>
          <volume>30</volume>
          <fpage>416</fpage>
          <lpage>420</lpage>
          <pub-id pub-id-type="doi">10.1038/ng859</pub-id>
          <pub-id pub-id-type="pmid">11925568</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garc&#xED;a-Garc&#xED;a</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>KV</given-names>
            </name>
          </person-group>
          <article-title>Essential role of glycosaminoglycans in Fgf signaling during mouse gastrulation</article-title>
          <source>Cell</source>
          <year>2003</year>
          <volume>114</volume>
          <fpage>727</fpage>
          <lpage>737</lpage>
          <pub-id pub-id-type="doi">10.1016/S0092-8674(03)00715-3</pub-id>
          <pub-id pub-id-type="pmid">14505572</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Choksi</surname>
              <given-names>SP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Systematic discovery of novel ciliary genes through functional genomics in the zebrafish</article-title>
          <source>Development</source>
          <year>2014</year>
          <volume>141</volume>
          <fpage>3410</fpage>
          <lpage>3419</lpage>
          <pub-id pub-id-type="doi">10.1242/dev.108209</pub-id>
          <pub-id pub-id-type="pmid">25139857</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lancaster</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Knoblich</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
          <article-title>Generation of cerebral organoids from human pluripotent stem cells</article-title>
          <source>Nat. Protoc.</source>
          <year>2014</year>
          <volume>9</volume>
          <fpage>2329</fpage>
          <lpage>2340</lpage>
          <pub-id pub-id-type="doi">10.1038/nprot.2014.158</pub-id>
          <pub-id pub-id-type="pmid">25188634</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Torisawa</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Katanin p80, NuMA and cytoplasmic dynein cooperate to control microtubule dynamics</article-title>
          <source>Sci. Rep.</source>
          <year>2017</year>
          <volume>7</volume>
          <fpage>1</fpage>
          <lpage>16</lpage>
          <pub-id pub-id-type="doi">10.1038/s41598-016-0028-x</pub-id>
          <pub-id pub-id-type="pmid">28127051</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chia</surname>
              <given-names>PH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A homozygous loss-of-function CAMK2A mutation causes growth delay, frequent seizures and severe intellectual disability</article-title>
          <source>Elife</source>
          <year>2018</year>
          <volume>7</volume>
          <fpage>1</fpage>
          <lpage>19</lpage>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hacker</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Perrimon</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>The Drosophila sugarless gene modulates Wingless signaling and encodes an enzyme involved in polysaccharide biosynthesis</article-title>
          <source>Development</source>
          <year>1997</year>
          <volume>124</volume>
          <fpage>3565</fpage>
          <lpage>3573</lpage>
          <pub-id pub-id-type="pmid">9342049</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lin</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Buff</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Perrimon</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Michelson</surname>
              <given-names>AM</given-names>
            </name>
          </person-group>
          <article-title>Heparan sulfate proteoglycans are essential for FGF receptor signaling during Drosophila embryonic development</article-title>
          <source>Development</source>
          <year>1999</year>
          <volume>126</volume>
          <fpage>3715</fpage>
          <lpage>3723</lpage>
          <pub-id pub-id-type="pmid">10433902</pub-id>
        </element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Superina</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Borovina</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ciruna</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Analysis of maternal-zygotic ugdh mutants reveals divergent roles for HSPGs in vertebrate embryogenesis and provides new insight into the initiation of left-right asymmetry</article-title>
          <source>Dev. Biol.</source>
          <year>2014</year>
          <volume>387</volume>
          <fpage>154</fpage>
          <lpage>166</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ydbio.2014.01.013</pub-id>
          <pub-id pub-id-type="pmid">24462977</pub-id>
        </element-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <mixed-citation publication-type="other">Perenthaler, E. et al. Loss of UGP2 in brain leads to a severe epileptic encephalopathy, emphasizing that bi- allelic isoform specific start-loss mutations of essential genes can cause genetic diseases. <italic>bioRxiv</italic> (2019). 10.1101/799841.</mixed-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Volpi</surname>
              <given-names>Stefano</given-names>
            </name>
            <name>
              <surname>Yamazaki</surname>
              <given-names>Yasuhiro</given-names>
            </name>
            <name>
              <surname>Brauer</surname>
              <given-names>Patrick M.</given-names>
            </name>
            <name>
              <surname>van Rooijen</surname>
              <given-names>Ellen</given-names>
            </name>
            <name>
              <surname>Hayashida</surname>
              <given-names>Atsuko</given-names>
            </name>
            <name>
              <surname>Slavotinek</surname>
              <given-names>Anne</given-names>
            </name>
            <name>
              <surname>Sun Kuehn</surname>
              <given-names>Hye</given-names>
            </name>
            <name>
              <surname>Di Rocco</surname>
              <given-names>Maja</given-names>
            </name>
            <name>
              <surname>Rivolta</surname>
              <given-names>Carlo</given-names>
            </name>
            <name>
              <surname>Bortolomai</surname>
              <given-names>Ileana</given-names>
            </name>
            <name>
              <surname>Du</surname>
              <given-names>Likun</given-names>
            </name>
            <name>
              <surname>Felgentreff</surname>
              <given-names>Kerstin</given-names>
            </name>
            <name>
              <surname>Ott de Bruin</surname>
              <given-names>Lisa</given-names>
            </name>
            <name>
              <surname>Hayashida</surname>
              <given-names>Kazutaka</given-names>
            </name>
            <name>
              <surname>Freedman</surname>
              <given-names>George</given-names>
            </name>
            <name>
              <surname>Marcovecchio</surname>
              <given-names>Genni Enza</given-names>
            </name>
            <name>
              <surname>Capuder</surname>
              <given-names>Kelly</given-names>
            </name>
            <name>
              <surname>Rath</surname>
              <given-names>Prisni</given-names>
            </name>
            <name>
              <surname>Luche</surname>
              <given-names>Nicole</given-names>
            </name>
            <name>
              <surname>Hagedorn</surname>
              <given-names>Elliott J.</given-names>
            </name>
            <name>
              <surname>Buoncompagni</surname>
              <given-names>Antonella</given-names>
            </name>
            <name>
              <surname>Royer-Bertrand</surname>
              <given-names>Beryl</given-names>
            </name>
            <name>
              <surname>Giliani</surname>
              <given-names>Silvia</given-names>
            </name>
            <name>
              <surname>Poliani</surname>
              <given-names>Pietro Luigi</given-names>
            </name>
            <name>
              <surname>Imberti</surname>
              <given-names>Luisa</given-names>
            </name>
            <name>
              <surname>Dobbs</surname>
              <given-names>Kerry</given-names>
            </name>
            <name>
              <surname>Poulain</surname>
              <given-names>Fabienne E.</given-names>
            </name>
            <name>
              <surname>Martini</surname>
              <given-names>Alberto</given-names>
            </name>
            <name>
              <surname>Manis</surname>
              <given-names>John</given-names>
            </name>
            <name>
              <surname>Linhardt</surname>
              <given-names>Robert J.</given-names>
            </name>
            <name>
              <surname>Bosticardo</surname>
              <given-names>Marita</given-names>
            </name>
            <name>
              <surname>Rosenzweig</surname>
              <given-names>Sergio Damian</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>Hane</given-names>
            </name>
            <name>
              <surname>Puck</surname>
              <given-names>Jennifer M.</given-names>
            </name>
            <name>
              <surname>Z&#xFA;&#xF1;iga-Pfl&#xFC;cker</surname>
              <given-names>Juan Carlos</given-names>
            </name>
            <name>
              <surname>Zon</surname>
              <given-names>Leonard</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>Pyong Woo</given-names>
            </name>
            <name>
              <surname>Superti-Furga</surname>
              <given-names>Andrea</given-names>
            </name>
            <name>
              <surname>Notarangelo</surname>
              <given-names>Luigi D.</given-names>
            </name>
          </person-group>
          <article-title>EXTL3 mutations cause skeletal dysplasia, immune deficiency, and developmental delay</article-title>
          <source>The Journal of Experimental Medicine</source>
          <year>2017</year>
          <volume>214</volume>
          <issue>3</issue>
          <fpage>623</fpage>
          <lpage>637</lpage>
          <pub-id pub-id-type="doi">10.1084/jem.20161525</pub-id>
          <pub-id pub-id-type="pmid">28148688</pub-id>
        </element-citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tian</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Loss of CHSY1, a secreted FRINGE enzyme, causes syndromic brachydactyly in humans via increased NOTCH signaling</article-title>
          <source>Am. J. Hum. Genet.</source>
          <year>2010</year>
          <volume>87</volume>
          <fpage>768</fpage>
          <lpage>778</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ajhg.2010.11.005</pub-id>
          <pub-id pub-id-type="pmid">21129727</pub-id>
        </element-citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reuter</surname>
              <given-names>MS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>NDST1 missense mutations in autosomal recessive intellectual disability</article-title>
          <source>Am. J. Med. Genet. Part A</source>
          <year>2014</year>
          <volume>164</volume>
          <fpage>2753</fpage>
          <lpage>2763</lpage>
          <pub-id pub-id-type="doi">10.1002/ajmg.a.36723</pub-id>
        </element-citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Muenzer</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Overview of the mucopolysaccharidoses</article-title>
          <source>Rheumatology</source>
          <year>2011</year>
          <volume>50</volume>
          <fpage>4</fpage>
          <lpage>12</lpage>
          <pub-id pub-id-type="doi">10.1093/rheumatology/ker394</pub-id>
          <pub-id pub-id-type="pmid">21078626</pub-id>
        </element-citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Soleman</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Filippov</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Dityatev</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Fawcett</surname>
              <given-names>JW</given-names>
            </name>
          </person-group>
          <article-title>Targeting the neural extracellular matrix in neurological disorders</article-title>
          <source>Neuroscience</source>
          <year>2013</year>
          <volume>253</volume>
          <fpage>194</fpage>
          <lpage>213</lpage>
          <pub-id pub-id-type="doi">10.1016/j.neuroscience.2013.08.050</pub-id>
          <pub-id pub-id-type="pmid">24012743</pub-id>
        </element-citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nishimura</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ishii</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kuraoka</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kamimura</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Maeda</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Opposing functions of chondroitin sulfate and heparan sulfate during early neuronal polarization</article-title>
          <source>Neuroscience</source>
          <year>2010</year>
          <volume>169</volume>
          <fpage>1535</fpage>
          <lpage>1547</lpage>
          <pub-id pub-id-type="doi">10.1016/j.neuroscience.2010.06.027</pub-id>
          <pub-id pub-id-type="pmid">20600662</pub-id>
        </element-citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <mixed-citation publication-type="other">Gangl, R., Behm&#xFC;ller, R. &amp; Tenhaken, R. Molecular cloning of a novel glucuronokinase/putative pyrophosphorylase from zebrafish acting in an UDP-glucuronic acid salvage pathway. <italic>PLoS ONE</italic><bold>9</bold>, e89690 (2014).</mixed-citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Durbin</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Fast and accurate long-read alignment with Burrows-Wheeler transform</article-title>
          <source>Bioinformatics</source>
          <year>2010</year>
          <volume>26</volume>
          <fpage>589</fpage>
          <lpage>595</lpage>
          <pub-id pub-id-type="doi">10.1093/bioinformatics/btp698</pub-id>
          <pub-id pub-id-type="pmid">20080505</pub-id>
        </element-citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tanaka</surname>
              <given-names>AJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mutations in SPATA5 are associated with microcephaly, intellectual disability, seizures, and hearing loss</article-title>
          <source>Am. J. Hum. Genet.</source>
          <year>2015</year>
          <volume>97</volume>
          <fpage>457</fpage>
          <lpage>464</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ajhg.2015.07.014</pub-id>
          <pub-id pub-id-type="pmid">26299366</pub-id>
        </element-citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Suls</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>De novo loss-of-function mutations in CHD2 cause a fever-sensitive myoclonic epileptic encephalopathy sharing features with dravet syndrome</article-title>
          <source>Am. J. Hum. Genet.</source>
          <year>2013</year>
          <volume>93</volume>
          <fpage>967</fpage>
          <lpage>975</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ajhg.2013.09.017</pub-id>
          <pub-id pub-id-type="pmid">24207121</pub-id>
        </element-citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reumers</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Optimized filtering reduces the error rate in detecting genomic variants by short-read sequencing</article-title>
          <source>Nat. Biotechnol.</source>
          <year>2011</year>
          <volume>30</volume>
          <fpage>61</fpage>
          <lpage>68</lpage>
          <pub-id pub-id-type="doi">10.1038/nbt.2053</pub-id>
          <pub-id pub-id-type="pmid">22178994</pub-id>
        </element-citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Farwell</surname>
              <given-names>KD</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Enhanced utility of family-centered diagnostic exome sequencing with inheritance model-based analysis: results from 500 unselected families with undiagnosed genetic conditions</article-title>
          <source>Genet. Med.</source>
          <year>2015</year>
          <volume>17</volume>
          <fpage>578</fpage>
          <lpage>586</lpage>
          <pub-id pub-id-type="doi">10.1038/gim.2014.154</pub-id>
          <pub-id pub-id-type="pmid">25356970</pub-id>
        </element-citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Neveling</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A post-hoc comparison of the utility of sanger sequencing and exome sequencing for the diagnosis of heterogeneous diseases</article-title>
          <source>Hum. Mutat.</source>
          <year>2013</year>
          <volume>34</volume>
          <fpage>1721</fpage>
          <lpage>1726</lpage>
          <pub-id pub-id-type="doi">10.1002/humu.22450</pub-id>
          <pub-id pub-id-type="pmid">24123792</pub-id>
        </element-citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <mixed-citation publication-type="other">McKenna, S. The genome analysis toolkit. <italic>Proc. Int. Conf. Intellect. Capital, Knowl. Manag. Organ. Learn</italic>. 254&#x2013;260 (2009). 10.1101/gr.107524.110.20</mixed-citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Flex</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Biallelic mutations in TBCD, encoding the tubulin folding cofactor D, perturb microtubule dynamics and cause early-onset encephalopathy</article-title>
          <source>Am. J. Hum. Genet.</source>
          <year>2016</year>
          <volume>99</volume>
          <fpage>962</fpage>
          <lpage>973</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ajhg.2016.08.003</pub-id>
          <pub-id pub-id-type="pmid">27666370</pub-id>
        </element-citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bauer</surname>
              <given-names>CK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mutations in KCNK4 that affect gating cause a recognizable neurodevelopmental syndrome</article-title>
          <source>Am. J. Hum. Genet.</source>
          <year>2018</year>
          <volume>103</volume>
          <fpage>621</fpage>
          <lpage>630</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ajhg.2018.09.001</pub-id>
          <pub-id pub-id-type="pmid">30290154</pub-id>
        </element-citation>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cingolani</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3</article-title>
          <source>Fly. (Austin).</source>
          <year>2013</year>
          <volume>5</volume>
          <fpage>29</fpage>
          <lpage>30</lpage>
        </element-citation>
      </ref>
      <ref id="CR51">
        <label>51.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>Xiaoming</given-names>
            </name>
            <name>
              <surname>Jian</surname>
              <given-names>Xueqiu</given-names>
            </name>
            <name>
              <surname>Boerwinkle</surname>
              <given-names>Eric</given-names>
            </name>
          </person-group>
          <article-title>dbNSFP v2.0: A Database of Human Non-synonymous SNVs and Their Functional Predictions and Annotations</article-title>
          <source>Human Mutation</source>
          <year>2013</year>
          <volume>34</volume>
          <issue>9</issue>
          <fpage>E2393</fpage>
          <lpage>E2402</lpage>
          <pub-id pub-id-type="doi">10.1002/humu.22376</pub-id>
          <pub-id pub-id-type="pmid">23843252</pub-id>
        </element-citation>
      </ref>
      <ref id="CR52">
        <label>52.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dong</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies</article-title>
          <source>Hum. Mol. Genet.</source>
          <year>2015</year>
          <volume>24</volume>
          <fpage>2125</fpage>
          <lpage>2137</lpage>
          <pub-id pub-id-type="doi">10.1093/hmg/ddu733</pub-id>
          <pub-id pub-id-type="pmid">25552646</pub-id>
        </element-citation>
      </ref>
      <ref id="CR53">
        <label>53.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jagadeesh</surname>
              <given-names>KA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>M-CAP eliminates a majority of variants of uncertain significance in clinical exomes at high sensitivity</article-title>
          <source>Nat. Genet.</source>
          <year>2016</year>
          <volume>48</volume>
          <fpage>1581</fpage>
          <lpage>1586</lpage>
          <pub-id pub-id-type="doi">10.1038/ng.3703</pub-id>
          <pub-id pub-id-type="pmid">27776117</pub-id>
        </element-citation>
      </ref>
      <ref id="CR54">
        <label>54.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>InterVar: clinical interpretation of genetic variants by the 2015 ACMG-AMP guidelines</article-title>
          <source>Am. J. Hum. Genet.</source>
          <year>2017</year>
          <volume>100</volume>
          <fpage>267</fpage>
          <lpage>280</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ajhg.2017.01.004</pub-id>
          <pub-id pub-id-type="pmid">28132688</pub-id>
        </element-citation>
      </ref>
      <ref id="CR55">
        <label>55.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bonifert</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pure and syndromic optic atrophy explained by deep intronic OPA1 mutations and an intralocus modifier</article-title>
          <source>Brain</source>
          <year>2014</year>
          <volume>137</volume>
          <fpage>2164</fpage>
          <lpage>2177</lpage>
          <pub-id pub-id-type="doi">10.1093/brain/awu165</pub-id>
          <pub-id pub-id-type="pmid">24970096</pub-id>
        </element-citation>
      </ref>
      <ref id="CR56">
        <label>56.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Spicer</surname>
              <given-names>AP</given-names>
            </name>
          </person-group>
          <article-title>Molecular cloning and characterization of the human and mouse UDP-glucose dehydrogenase genes</article-title>
          <source>J. Biol. Chem.</source>
          <year>1998</year>
          <volume>273</volume>
          <fpage>25117</fpage>
          <lpage>25124</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.273.39.25117</pub-id>
          <pub-id pub-id-type="pmid">9737970</pub-id>
        </element-citation>
      </ref>
      <ref id="CR57">
        <label>57.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grady</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Inhibiting hexamer disassembly of human UDP-glucose dehydrogenase by photoactivated amino acid cross-linking</article-title>
          <source>Biochemistry</source>
          <year>2016</year>
          <volume>55</volume>
          <fpage>3157</fpage>
          <lpage>3164</lpage>
          <pub-id pub-id-type="doi">10.1021/acs.biochem.6b00259</pub-id>
          <pub-id pub-id-type="pmid">27198584</pub-id>
        </element-citation>
      </ref>
      <ref id="CR58">
        <label>58.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zimmer</surname>
              <given-names>BM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Loss of exogenous androgen dependence by prostate tumor cells is associated with elevated glucuronidation potential</article-title>
          <source>Horm. Cancer</source>
          <year>2016</year>
          <volume>7</volume>
          <fpage>260</fpage>
          <lpage>271</lpage>
          <pub-id pub-id-type="doi">10.1007/s12672-016-0268-z</pub-id>
          <pub-id pub-id-type="pmid">27307252</pub-id>
        </element-citation>
      </ref>
      <ref id="CR59">
        <label>59.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yakoub</surname>
              <given-names>Abraam M.</given-names>
            </name>
            <name>
              <surname>Sadek</surname>
              <given-names>Mark</given-names>
            </name>
          </person-group>
          <article-title>Development and Characterization of Human Cerebral Organoids</article-title>
          <source>Cell Transplantation</source>
          <year>2018</year>
          <volume>27</volume>
          <issue>3</issue>
          <fpage>393</fpage>
          <lpage>406</lpage>
          <pub-id pub-id-type="doi">10.1177/0963689717752946</pub-id>
          <pub-id pub-id-type="pmid">29749250</pub-id>
        </element-citation>
      </ref>
      <ref id="CR60">
        <label>60.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chambers</surname>
              <given-names>SM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling</article-title>
          <source>Nat. Biotechnol.</source>
          <year>2009</year>
          <volume>27</volume>
          <fpage>275</fpage>
          <lpage>280</lpage>
          <pub-id pub-id-type="doi">10.1038/nbt.1529</pub-id>
          <pub-id pub-id-type="pmid">19252484</pub-id>
        </element-citation>
      </ref>
      <ref id="CR61">
        <label>61.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xu</surname>
              <given-names>X</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Reversal of phenotypic abnormalities by CRISPR/Cas9-mediated gene correction in Huntington disease patient-derived induced pluripotent stem cells</article-title>
          <source>Stem Cell Rep.</source>
          <year>2017</year>
          <volume>8</volume>
          <fpage>619</fpage>
          <lpage>633</lpage>
          <pub-id pub-id-type="doi">10.1016/j.stemcr.2017.01.022</pub-id>
        </element-citation>
      </ref>
      <ref id="CR62">
        <label>62.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Radulescu</surname>
              <given-names>CI</given-names>
            </name>
            <name>
              <surname>Utami</surname>
              <given-names>KH</given-names>
            </name>
            <name>
              <surname>Pouladi</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Obtaining multi-electrode array recordings from human induced pluripotent stem cell&#x2013;derived neurons</article-title>
          <source>Bio-Protoc.</source>
          <year>2017</year>
          <volume>7</volume>
          <fpage>e2609</fpage>
        </element-citation>
      </ref>
      <ref id="CR63">
        <label>63.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Walsh</surname>
              <given-names>EC</given-names>
            </name>
            <name>
              <surname>Stainier</surname>
              <given-names>DY</given-names>
            </name>
          </person-group>
          <article-title>UDP-glucose dehydrogenase required for cardiac valve formation in zebrafish</article-title>
          <source>Sci. (N. Y., NY)</source>
          <year>2001</year>
          <volume>293</volume>
          <fpage>1670</fpage>
          <lpage>1673</lpage>
          <pub-id pub-id-type="doi">10.1126/science.293.5535.1670</pub-id>
        </element-citation>
      </ref>
      <ref id="CR64">
        <label>64.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wilkinson</surname>
              <given-names>RN</given-names>
            </name>
            <name>
              <surname>Elworthy</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ingham</surname>
              <given-names>PW</given-names>
            </name>
            <name>
              <surname>van Eeden</surname>
              <given-names>FJM</given-names>
            </name>
          </person-group>
          <article-title>A method for high-throughput PCR-based genotyping of larval zebrafish tail biopsies</article-title>
          <source>Biotechniques</source>
          <year>2013</year>
          <volume>55</volume>
          <fpage>314</fpage>
          <lpage>316</lpage>
          <pub-id pub-id-type="doi">10.2144/000114116</pub-id>
          <pub-id pub-id-type="pmid">24344681</pub-id>
        </element-citation>
      </ref>
      <ref id="CR65">
        <label>65.</label>
        <mixed-citation publication-type="other">Pena, I. A. et al. Pyridoxine-dependent epilepsy in zebra fish caused by Aldh7a1 deficiency. <bold>207</bold>, 1501&#x2013;1518 (2017).</mixed-citation>
      </ref>
      <ref id="CR66">
        <label>66.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Appenzeller</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>De novo mutations in synaptic transmission genes including DNM1 cause epileptic encephalopathies</article-title>
          <source>Am. J. Hum. Genet.</source>
          <year>2014</year>
          <volume>95</volume>
          <fpage>360</fpage>
          <lpage>370</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ajhg.2014.08.013</pub-id>
          <pub-id pub-id-type="pmid">25262651</pub-id>
        </element-citation>
      </ref>
      <ref id="CR67">
        <label>67.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Guex</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Peitsch</surname>
              <given-names>MC</given-names>
            </name>
          </person-group>
          <article-title>SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modeling</article-title>
          <source>Electrophoresis</source>
          <year>1997</year>
          <volume>18</volume>
          <fpage>2714</fpage>
          <lpage>2723</lpage>
          <pub-id pub-id-type="doi">10.1002/elps.1150181505</pub-id>
          <pub-id pub-id-type="pmid">9504803</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>